U.S. patent application number 11/978730 was filed with the patent office on 2009-07-02 for heteroclitic analogs and related methods.
Invention is credited to John D. Fikes, Glenn Ishioka, Alessandro Sette, Shabnam Tangri.
Application Number | 20090169574 11/978730 |
Document ID | / |
Family ID | 26862329 |
Filed Date | 2009-07-02 |
United States Patent
Application |
20090169574 |
Kind Code |
A1 |
Tangri; Shabnam ; et
al. |
July 2, 2009 |
Heteroclitic analogs and related methods
Abstract
Heteroclitic analogs of Class I epitopes are prepared by
providing conservative or semi-conservative amino acid
substitutions at positions 3 and/or 5 and/or 7 of these epitopes.
The analogs are useful in eliciting immune responses with respect
to the corresponding wildtype epitopes.
Inventors: |
Tangri; Shabnam; (San Diego,
CA) ; Sette; Alessandro; (La Jolla, CA) ;
Ishioka; Glenn; (Solana Beach, CA) ; Fikes; John
D.; (San Diego, CA) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Family ID: |
26862329 |
Appl. No.: |
11/978730 |
Filed: |
October 30, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10116118 |
Apr 5, 2002 |
|
|
|
11978730 |
|
|
|
|
PCT/US00/31856 |
Nov 20, 2000 |
|
|
|
10116118 |
|
|
|
|
60166529 |
Nov 18, 1999 |
|
|
|
60239008 |
Oct 6, 2000 |
|
|
|
Current U.S.
Class: |
424/185.1 ;
424/450; 530/326; 530/327; 530/328 |
Current CPC
Class: |
C07K 14/71 20130101;
C07K 14/4748 20130101; C07K 7/06 20130101; A61K 38/00 20130101;
A61P 31/04 20180101; A61P 31/12 20180101; C07K 2319/00 20130101;
A61K 39/00 20130101; A61P 35/00 20180101; C07K 7/08 20130101; A61P
31/10 20180101; C07K 14/70503 20130101; A61P 37/04 20180101; A61P
33/00 20180101; A61K 2039/555 20130101; C07K 14/70539 20130101 |
Class at
Publication: |
424/185.1 ;
530/328; 530/327; 530/326; 424/450 |
International
Class: |
A61K 9/127 20060101
A61K009/127; C07K 7/06 20060101 C07K007/06; C07K 7/08 20060101
C07K007/08; A61K 39/00 20060101 A61K039/00 |
Claims
1-11. (canceled)
12. A peptide comprising an analog of a Major Histocompatibility
Complex (MHC) class I peptide epitope, wherein said analog has
enhanced immunogenicity compared to said epitope, and wherein said
peptide analog is prepared by: a) identifying a MHC class I epitope
comprising a formula (A), wherein formula (A) is
Rn-R2-R3-R4-R5-R6-R7- . . . Rx, Rn is the N-terminal amino acid, Rx
is the C-terminal amino acid, x=8-11 such that Rx can be from the
eighth to the eleventh amino acid residue from Rn, R2 or R3 and Rx
are primary anchor residues of a motif or supermotif, and b)
producing a polypeptide comprising an analog, said analog
comprising a formula (B) identical to said formula (A) except one
or more conservative or semiconservative amino acid substitutions
at R3 and/or R5 and/or R7, provided said one or more substitutions
is not of a primary anchor residue.
13-15. (canceled)
16. A composition comprising at least the peptide of claim 12.
17. The composition of claim 16, wherein the peptide contains 9-15
amino acids.
18. The composition of claim 16, wherein the peptide comprises an
amino acid sequence selected from the group consisting of SEQ ID
NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID
NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ
ID NO:17, SEQ ID NO:19 and SEQ ID NO:20.
19. A composition of claim 16, wherein the peptide is admixed or
joined to a CTL epitope.
20. A composition of claim 16, wherein the peptide is admixed or
joined to an HTL epitope.
21. A composition of claim 20, wherein the HTL epitope is a pan-DR
binding molecule.
22. A composition of claim 16, further comprising a liposome.
23. A composition of claim 16, wherein the epitope is coupled to a
lipid.
24. A composition of claim 16, wherein said epitope is included in
a heteropolymer.
25. A composition of claim 16, wherein the epitope is included in a
homopolymer.
26-30. (canceled)
31. The composition of claim 16, further comprising a label.
32. The composition of claim 31, wherein the label is biotin, a
fluorescent moiety, a non-mammalian sugar, a radio label or a small
molecule to which a monoclonal antibody binds.
33. The composition of claim 16 which is a vaccine containing: a
unit dosage of said peptide, and a pharmaceutical excipient.
34-39. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of
International Application No. PCT/US00/31856, filed Nov. 20, 2000,
which published under PCT article 21(2) in English, and which
claims the benefit of U.S. Provisional Patent Application No.
60/166,529, filed 18 Nov. 1999, and U.S. Provisional Patent
Application No. 60/239,008, filed 6 Oct. 2000; each of said
applications is incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] The invention relates to methods for generating heteroclitic
analogs of an original peptide which have increased stimulatory
capacity for a given T cell.
[0003] Several studies suggest the cytotoxic T lymphocytes (CTLs)
play a central role in the eradication of infectious disease and
cancer by the immune system (Byrne, et al., J. Immunol. 51:682
(1984), McMichael, et al., N. England J. Med., 309:13 (1983)).
Since CTLs are stimulated by peptides comprising epitopes,
considerable effort is ongoing in developing epitope-based vaccines
that stimulate CTL responses. One class of epitopes, designated
heteroclitic analogs; provides benefit as vaccine components since
these analogs induce T cell responses stronger than those induced
by the native epitope. Heteroclitic analogs are defined as peptides
having increased stimulatory capacity or potency for a specific T
cell, as measured by increased responses to a given dose, or by a
requirement of lesser amounts to achieve the same response.
[0004] The advantages associated with using heteroclitic analogs in
clinical applications are as follows. First, heteroclitic analogs
have the ability to break/overcome tolerance by reversing a state
of T cell anergy, activating non-tolerized cross-reactive clones of
T cells, or by mediating "immune deviation," i.e., the type of CTL
produced, such as Th1 or Th2. Recent studies indicate that
heteroclitic analogs are immunogenic (Zaremba, et al., Cancer
Research, 57:4570 (1997); Rivoltoni, et al., Cancer Research,
59:301 (1999); Selby, et al., 162 (2):669 (1999)) in that they are
capable of inducing CTLs that recognize endogenously processed
epitope. This is confirmed by studies in different immunological
systems (Zugel, et al., J. Immunol., 161:1705 (1998), Wang, et al.,
J. Exp. Med., 190:983 (1999), Men, et al., J. Immunol., 162:3566,
(1999)). For example, studies by Zugel et al. (Zugel, et al, supra)
have shown that T cell tolerance to an immunodominant T cell
epitope in adult mice can be overcome by immunization with
heteroclitic cross-reactive peptide analogs of that peptide.
[0005] This is particularly significant in the field of cancer
vaccines, where most of the CTL epitopes are derived from self
antigens. Due to the fact that cancer related antigens are often
self-antigens there is a corresponding phenomenon that there may be
preexisting tolerance to these antigens, whereby generation of a T
cell response to such epitopes is a challenge. Breaking of
tolerance by heteroclitic analogs has been shown in a recent study
in a murine Class II system (Wang, et al., J. Exp. Med. 190:983
(1999)). In this study, the mechanism involved in breaking of
tolerance was the stimulation of nontolerized, low affinity clones,
rather than reversal of anergy. The heteroclicity demonstrated
herein is associated with the induction of high avidity CTL, this
represents an important difference.
[0006] Second, peptide analogs have been demonstrated to modulate
cytokine production from T cells (Pfeiffer, et al., J. Exp. Med.,
181:1569 (1995), Tao, et al., J. Immunol., 158:4237 (1997),
Salazar, et al., Int. J. Cancer 85 (6):829-38 (2000), Nicholson, et
al., Int. Immunol. 12 (2):205-13 (2000)). The immune deviation
induced by such analogs has implications in several disease states,
where generation of a specific subset of Th cell responses
correlate with tumor regression (Zitvogel, et al., J. Exp. Med.,
183:87 (1996), Celluzzi, et al., J. Exp. Med. 183:283 (1996)) or
affected the clinical outcome of autoimmune or infectious disease
(Romagnani, et al., Annu. Rev. Immunol., 12:227-57 (1994)). Thus,
immunization with heteroclitic analogs offers the capacity to
modulate cytokine production by induction of specific subsets of
effector T cells, thereby altering the course of disease.
[0007] Third, heteroclitic analogs offer an advantage in drug
development since significantly smaller amounts of peptide are
needed for treatment doses, due to their strong biological potency.
This feature overcomes certain manufacturing and toxicity concerns.
In this regard, it has been shown that a heteroclitic analog of a
MART-1 peptide (Rivoltini, et al., Cancer Research 59:301 (1999)),
which generated antigen specific T cells in melanoma patients, was
active at much lower concentrations than the native epitope.
Similar results were reported by Schlom and colleagues (Zaremba, et
al., Cancer Research 57:4570 (1997)) regarding heteroclitic analog
of the CEA derived CAP1 epitope. However, a side-by-side precursor
frequency analysis or a TCR avidity analysis against wildtype
peptide was not performed.
[0008] Accordingly, because of their biological relevance, it would
be extremely useful to predict amino acid substitutions that render
heteroclitic activity to a given epitope. However, prior to the
present disclosure there has been no easy method for predicting
such substitutions. Indeed, in previous studies (Selby, et al., J.
Immunol, 162 (2):669 (1999), Skipper, et al., J. Exp. Med. 183:527
(1996)), heteroclitic epitopes were fortuitously identified by
eluting naturally occurring mutant peptides from melanoma cells, or
by systematically screening a large number of analogs consisting of
substitutions at almost every position in the epitope (Zaremba, et
al, Cancer Research, 57:4570 (1997), Loftus, et al., Cancer
Research 58:2433 (1998), Blake, et al., J. Exp. Med. 18:121
(1996)). Alternatively, heteroclitic analogs were identified by
screening random combinatorial peptide libraries which also has
required the arduous synthesis and screening of large numbers of
peptides (Pinilla, et al., Current Opinion in Immunology 11:193-202
(1999)). Genetic approaches, such as screening of DNA expression
libraries, have provided another method for generating CTL epitopes
and analogs (Boon, et al., Annu. Rev. Immunol. 12:337-65 (1994),
Gavin, et al., Eur. J. Immunol. 24 (9):2124-33 (1994)). However,
this approach may be problematic given the potentially small
quantities and complexity of epitopes generated.
BRIEF SUMMARY OF THE INVENTION
[0009] The invention provides methods to prepare peptides
containing epitopes which have enhanced ability to effect an immune
response with respect to corresponding analogous wildtype epitopes.
The resulting "heteroclitic analogs" are useful in immunological
compositions for treatment of viral diseases, cancer, and other
conditions which are characterized by displayed antigens on target
cells.
[0010] Thus, in one aspect, the invention is directed to a method
to enhance the immunogenicity of a peptide containing an epitope,
the method comprising i) providing a peptide comprising a first
Class I epitope wherein said epitope consists essentially of an
amino acid sequence having an N-terminus and a C-terminus and at
least one primary anchor residue, wherein amino acid residues of
the epitope are numbered consecutively and the primary anchor
residue nearest the N-terminus of the epitope is at position 2 or
position 3; and ii) introducing one or more conservative or
semi-conservative substitution between the N-terminus and the
C-terminus of the epitope at position 3 and/or 5 and/or 7 which
position does not contain a primary anchor residue, thereby
constructing a peptide comprising a second Class I epitope which
exhibits enhanced immunogenicity compared to the first Class I
epitope.
[0011] In another aspect, in the case of B7 superfamily epitopes,
the invention is directed to a method to enhance the immunogenicity
of a peptide containing a B7 superfamily epitope, the method
comprising i) providing a peptide comprising a first Class I
epitope which is a B7 superfamily epitope wherein said epitope
consists essentially of an amino acid sequence having an N-terminus
and a C-terminus and at least one primary anchor residue, wherein
amino acid residues of the epitope are numbered consecutively and
the primary anchor residue nearest the N-terminus of the epitope is
at position 2; and ii) introducing one or more conservative,
semi-conservative, or non-conservative substitution between the
N-terminus and the C-terminus of the epitope at position 3 and/or 5
and/or 7, thereby constructing a peptide comprising a second Class
I epitope which is a B7 superfamily epitope which exhibits enhanced
immunogenicity compared to the first Class I epitope.
[0012] Thus, the invention relates to a method of producing a
polypeptide comprising an analog of a MHC class I epitope, wherein
the analog has enhanced immunogenicity compared to the epitope,
comprising (a) identifying a MHC class I epitope comprising a
formula (A), wherein formula (A) is Rn-R2-R3-R4-R5-R6-R7- . . . Rx,
Rn is the N-terminal amino acid, Rx is the C-terminal amino acid,
x=8-11 such that Rx can be from the eighth to the eleventh amino
acid residue from Rn, R2 or R3 and Rx are primary anchor residues
of a motif or supermotif, and (b) producing a polypeptide
comprising an analog, said analog comprising a formula (B)
identical to said formula (A) except one or more conservative or
semiconservative amino acid substitutions at R3 and/or R5 and/or
R7, provided said one or more substitutions is not of a primary
anchor residues.
[0013] In some aspects, said analog comprises a formula (B)
identical to said formula (A) except that R3 is Met, provided R3 is
not an anchor residue of said motif or supermotif.
[0014] In some aspects, said analog comprises a formula (B)
identical to said formula (A) except that R5 is Met.
[0015] In some aspects, said analog comprises a formula (B)
identical to said formula (A) except that R7 is Met.
[0016] In some aspects, R3 is Ile in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R3 is Met.
[0017] In some aspects, R3 is Lys in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R3 is His or Leu.
[0018] In some aspects, R5 is Val in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R5 is His.
[0019] In some aspects, R5 is Leu in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R5 is Ile.
[0020] In some aspects, R5 is Val in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R5 is Ile or Phe.
[0021] In some aspects, R7 is His in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R7 is Trp.
[0022] In some aspects, R7 is Ala in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R7 is Pro.
[0023] In some aspects, R7 is Tyr in formula (A), and said analog
comprises a formula (B) identical to said formula (A) except that
R7 is His or Met.
[0024] In other aspects, the invention relates to a method of
producing a polypeptide comprising an analog of a MHC class I
epitope, wherein the analog has enhanced immunogenicity compared to
the epitope, comprising (a) identifying a MHC class I epitope
comprising a formula (A), wherein formula (A) is
Rn-R2-R3-R4-R5-R6-R7- . . . Rx, Rn is the N-terminal amino acid, Rx
is the C-terminal amino acid, x=8-11 such that Rx can be from the
eighth to the eleventh amino acid residue from Rn, R2 or R3 and Rx
are primary anchor residues of a motif or a supermotif, and (b)
producing a polypeptide comprising an analog, said analog
comprising a formula (B) identical to said formula (A) except one
or more nonconservative amino acid substitutions at R3 and/or R5
and/or R7.
[0025] Thus, in some aspects, R7 is Tyr in formula (A), and said
analog comprises a formula (B) identical to said formula (A) except
that R7 is Gly, Glu, or Asp.
[0026] The second Class I epitope described above is generically
referred to as a "heteroclitic analog" or an "analog."
[0027] In a preferred embodiment, the heteroclitic analog exhibits
at least about 50% increased potency for a specific T-cell compared
to the corresponding wildtype Class I epitope. The analog may
contain only one substitution, or may contain two or three, and the
substitution may be conservative or semi-conservative or, in the
case of a B7 superfamily epitope, non-conservative. The
heteroclitic analog may induce both Th1 and Th2 cytokines when
bound by an HLA Class I molecule and contacted with the relevant
cytotoxic T-cell. Preferably, the Class I epitope comprises an HLA
supermotif selected from the group consisting of A1, A2, A3, A24,
B7, B27, B44, B58 and B62, more preferably, the Class I epitope
comprises an A2 supermotif or a B7 supermotif, most preferably, an
A2.1 motif (e.g. an A*0201), or a B7 motif (e.g. a B*0702
motif).
[0028] The class I epitope may be from a viral antigen, a
tumor-associated antigen, a parasitic antigen, a bacterial antigen
or a fungal antigen.
[0029] The supermotif may be A1, wherein R2 is a primary anchor
residue and is either T, I, L, V, M or S, and Rx is either F, W, or
Y.
[0030] The supermotif may be A2, wherein R2 is a primary anchor
residue and is either L, I, V, M, A, T, or Q, and Rx is I, V, M, A,
T, or L.
[0031] The supermotif may be A2.1, wherein R2 is a primary anchor
and is either L, M, V, Q, I, A, or T, and Rx is either V, L, I, M,
A, or T.
[0032] The supermotif may be A3, wherein R2 is a primary anchor
residue and is either V, S, M, A, T, L, or I, and Rx is R or K.
[0033] The supermotif may be A24, wherein R2 is a primary anchor
residue and is either Y, f, W, I, V, L, M, or T, and Rx is either
F, I, Y, W, L, or M.
[0034] The supermotif may be B7, wherein R2 is a primary anchor
residue and is P and Rx is either V, I, L, F, M, W, Y, or A.
[0035] The invention also provides methods of inducing a human
cytotoxic T cell response against a preselected Class I peptide
epitope, the method comprising providing the heteroclitic analog
described above; and contacting a human CTL with the heteroclitic
analog.
[0036] In some aspects, the step of contacting is carried out in
vitro. In some aspects, the step of contacting is carried out by
administering to a subject a nucleic acid molecule comprising a
sequence encoding the heteroclitic analog peptide epitope.
[0037] The invention also provides polypeptides produced by the
method described above. The invention is also directed to peptides,
e.g., polypeptides, comprising the heteroclitic analog epitopes
which are obtainable by the method described above. In particular,
and preferably, such peptides include those where the epitope
(e.g., analog) consists of an amino acid sequence selected from the
group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ
ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12,
SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID
NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ
ID NO:26, SEQ ID NO:27, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51,
SEQ ID NO:52, and SEQ ID NO:53. The peptide may contain 9-20 amino
acids, preferably 9-16, more preferably 9-15, but may also contain
only a total of 9, 10, 11, 12, 13 or 14 amino acids. The defined
heteroclitic analog epitopes may be included in a longer
polypeptide or protein which is a homopolymer of the same epitope
(e.g., analog) or a heteropolymer which contains a variety of such
epitopes (e.g., analogs) or the heteroclitic analog epitope in
combination with wildtype epitopes. These peptides and proteins may
be included in compositions which are designed for pharmaceutical
use.
[0038] The peptides or heteropolymers or homopolymers containing
the heteroclitic analog epitopes may be combined with other
components to enhance further or modulate their activity in
eliciting an immune response. These additional varieties may be
covalently bound or non-covalently included in a mixture.
[0039] Thus, the polypeptide may comprise a T helper peptide, a
spacer or linker amino acid, a carrier, may be linked to a lipid,
may comprise a fusion protein, may comprise a homopolymer, a
heteropolymer, and/or may comprise one or more second epitopes or
second analogs.
[0040] Further, the heteroclitic analog epitope may be admixed or
joined to a CTL epitope, or to an HTL epitope, especially where HTL
epitope is a pan-DR binding molecule. A composition containing the
heteroclitic analog epitope may further comprise a liposome,
wherein the epitope is on or within the liposome, or the epitope
may be joined to a lipid. The heteroclitic epitope may be bound to
an HLA heavy chain, .beta.2-microglobulin, and strepavidin complex,
whereby a tetramer is formed. In addition, the heteroclitic epitope
(e.g., a polypeptide comprising an analog) may be modified in a
composition which comprises an antigen presenting cell, wherein the
epitope (e.g., a polypeptide comprising an analog) is on or within
the antigen presenting cell, wherein the epitope (e.g., a
polypeptide comprising an analog) is bound to an HLA molecule on
the antigen presenting cell. Thus, when a cytotoxic lymphocyte
(CTL) that is restricted to the HLA molecule is present, a receptor
of the CTL binds to a complex of the HLA molecule and the epitope
(e.g., a polypeptide comprising an analog). The antigen presenting
cell may be a dendritic cell. The composition may also simply
comprise an HLA molecule, wherein the peptide containing the
epitope (e.g., a polypeptide comprising an analog) is bound by the
HLA molecule. The composition may also comprise a label--e.g.,
biotin, a fluorescent moiety, a non-mammalian sugar, a radiolabel
or a small molecule to which a monoclonal antibody binds.
[0041] The compositions described are useful in eliciting an immune
response against the corresponding wildtype epitope. Typically, the
heteroclitic analog is included in such compositions which will
further contain suitable excipients. The active component
heteroclitic epitopes (e.g., a polypeptide comprising an analog)s
may be present in unit dosage form. Compositions useful in treating
subjects may also comprise nucleic acid molecules that encode the
peptides described above optionally including control sequences for
their expression.
BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
[0042] FIGS. 1A-1D. FIGS. 1A and 1B represent the results of
testing a panel of analogs of CEA.691 and MAGE3.112 respectively
for ability to induce IFN.gamma. production in the corresponding
CTL. FIGS. 1C and 1D are the corresponding dose response curves for
CEA.691 and MAGE3.112 heteroclitic analogs respectively.
[0043] FIGS. 2A-2D. FIGS. 2A, 2B and 2C show the results of testing
panels of analogs of MAGE2.157, HIVPol.476, and HBVPol.455 epitope
analogs with respect to the ability of these analogs to induce
IFN.gamma. production in the corresponding CTLs. FIG. 2D is the
relevant dose response curve for the successful HIVPol.476
analogs.
[0044] FIGS. 3A and 3B show dose response curves of heteroclitic
analogs of MAGE2.157 in comparison to wildtype with regard to their
ability to induce IFN.gamma. production or IL10 production from the
appropriate CTLs.
[0045] FIGS. 4A and 4B are the dose response curves for wildtype
and a heteroclitic analog of HIVPol.476 to produce IFN.gamma. and
IL10 in appropriate CTLs.
[0046] FIG. 5 shows the results of testing a panel of potential
heteroclitic analogs of the epitope p53.149M2 with respect to
IFN.gamma. production from appropriate CTLs.
[0047] FIGS. 6A and 6B are the corresponding dose response curves
for production of IFN.gamma. and IL10 by successful heteroclitic
analogs of p53.149M2.
[0048] FIG. 7 shows the results of testing a panel of potential
analogs of p53.Mu184 epitope for IFN.gamma. production in CTLs.
[0049] FIG. 8 shows the dose response curve for wildtype and two
successful heteroclitic analogs of p53.Mu184 with respect to
IFN.gamma. production.
[0050] FIGS. 9A-9D show the cross-reactivity of heteroclitic
analogs with regard to the corresponding wildtype epitope. In FIGS.
9A and 9B, IFN.gamma. production is plotted as a function of
concentration using stimulation by the immunizing peptide. FIGS. 9C
and 9D show the corresponding results when wildtype epitope is used
as the stimulant as opposed to the heteroclitic analog used for the
initial induction of CTL.
[0051] FIG. 10 shows the IFN.gamma. release with respect to
stimulation by p53.261 and its heteroclitic analogs.
[0052] FIG. 11 shows Elispot results with respect to various
heteroclitic analogs.
[0053] FIGS. 12A-12C show the results of stimulation of CTL
activity against endogenous peptide using various heteroclitic
analogs.
[0054] FIGS. 13A-13B show the results of testing a panel of
potential heteroclitic analogs of the epitope MAGE2.170 with
respect to IFN.gamma. production from appropriate CTLs. Single
residue substitutions, either conservative/semi-conservative or
non-conservative in nature, were introduced in the MAGE2.170
epitope at every non-MHC anchor position. Peptide analogs were
screened for their capacity to stimulate a human CTL line specific
for the MAGE2.170 wildtype epitope at two peptide doses. CTL
responses were measured by stimulating CTL in vitro with peptide at
the two indicated doses in the presence of GM3107 tumor cells as
APC. IFN.gamma. production of stimulated CTL was measured by ELISA.
The x-axis shows the substituted residue (underlined residues
denote non-conservative substitutions) and each response bar
corresponds to the stimulatory activity of that analog. The native
residue at the given position in the MAGE2.170 epitope is shown at
the top of each panel.
[0055] FIG. 14 shows dose response curves of heteroclitic analogs
of MAGE2.170 in comparison to wildtype with regard to their ability
to induce IFN.gamma.. Analogs with hyperstimulatory activity
identified in the initial screening assay were tested for CTL
stimulation in a peptide dose titration. Each analog was tested in
a dose titration against a human CTL line specific for the wildtype
epitope and GM3107 cells as APC. IFN.gamma. release was measured
with an ELISA.
MODES OF CARRYING OUT THE INVENTION
1. Overview
[0056] The present invention relates to methods of designing
heteroclitic analogs that bind to HLA Class I molecules.
"Heteroclitic analogs," as described herein, are peptides
comprising epitopes with increased potency for a specific T cell,
as measured by increased responses to a given dose, or by a
requirement of lesser amounts to achieve the same response as a
homologous Class I peptide. The methods of the invention are useful
to modify any Class I peptide, particularly those associated with
human cancers and precancerous conditions, and from infectious
agents such as viruses, bacteria, fungi, and protozoal
parasites.
[0057] Importantly, the phenomenon of heteroclicity applies across
HLA molecules that bind a particular Class I peptide. For example,
a heteroclitic analog peptide bearing the A2 supermotif is
heteroclitic (i.e., has higher potency) across all HLA molecules in
the HLA-supertype (e.g., A*0201, A*0202, A*0203, A*0204, A*0205,
A*0206, A*0207, etc.; see Table 5). Similarly, a heteroclitic
analog peptide bearing the B7 supermotif is heteroclitic across all
HLA molecules in the HLA-supertype (e.g., B*0702, B*0703, B*0704,
B*0705, B*1508, B*3501, B*3502, B*3503, B*3503, B*3504, B*3505,
B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105,
B*5301, B*5401, B*5501, B*5502, B*5601, B*5602, B*6701, B*7801,
etc.; see Table 5). Thus, a heteroclitic analog peptide bearing a
different sequence motif (e.g., A1, A2, A3, A24, B7, B27, B44, B58,
B62, etc.) induces a more potent immune response across all HLA
molecules within their specific HLAsuperfamily.
[0058] Applicants have found specific rules for designing
heteroclitic analogs which enhance the immune response to the
corresponding wildtype epitope. These rules are applicable with
respect to epitopes bearing motifs or supermotifs which bind to HLA
molecules encoded by any Class I allele. By using these rules, it
is possible to enhance the immunogenicity, therefore, of any
"wildtype" or "native" Class I epitope.
[0059] Briefly, the rules state that the wildtype Class I epitope
is modified by substituting a conservative or semi-conservative
amino acid as position 3 and/or 5 and/or 7 of the epitope. For B7
superfamily epitopes, the rule states that the wildtype Class I
epitope (i.e., the B7 superfamily epitope) is modified by
substituting a conservative or semi-conservative or
non-conservative amino acid as position 3 and/or 5 and/or 7 of the
epitope. The nature of the conservative or semi-conservative or
non-conservative amino acid to be substituted is defined by the
description in Preparation B hereinbelow, the results of which are
summarized in Table 2. Thus, by consulting Table 2, one can
determine suitable candidates for substitution at these positions.
As shown in Table 2, each of the amino acids shown across the top
of the table bears a numerically defined relationship to the
remaining 19 genetically encoded amino acids. The lower the index,
the higher the conservation; the same amino acid will have a
similarity assignment of 1.0; maximally different amino acids will
have similarity assignments approaching 20. Using the method set
forth in Preparation B, amino acids which are not gene-encoded can
also be assigned similarity indices and can be classified with
respect to any natively occurring amino acid as conservative or
semi-conservative (or non-conservative).
[0060] Heteroclitic analog peptides of the invention are
particularly useful to induce an immune response against antigens
to which a subject's immune system has become tolerant. Human
subjects are particularly preferred, but the methods can also be
applied to other mammals such as laboratory mice, taking account of
the corresponding HLA motifs with regard to these subjects.
Tolerance refers to a specific immunologic nonresponsiveness
induced by prior exposure to an antigen. Tolerance can be overcome
by identifying a particular Class I peptide epitope to which a
patient is tolerant, modifying the peptide epitope sequence
according to the methods of the invention, and inducing an immune
response that cross-reacts against the tolerized epitope (antigen).
Overcoming tolerance is particularly desirable, for example, when
the immune system of the subject is tolerant of a viral or
tumor-associated antigen, the latter antigens being often
over-expressed self-proteins as a consequence of cell
transformation.
[0061] To determine rules for designing heteroclitics, several
different CTL lines were screened for reactivity against panels of
analogs. Modification of T cell stimulatory capacity was achieved
with no alternation of the primary MHC anchors.
[0062] The wildtype epitopes include tumor epitopes derived from
self antigens that are specifically up-regulated in epithelial cell
cancers and have been shown to be immunogenic. Viral epitopes used,
such as those from the polymerase genes of the HIV and HBV, have
been shown to be immunogenic as well.
[0063] The rules described herein provide a basis to design
heteroclitic analogs, drastically reducing the screening otherwise
required and are extremely useful in designing epitope-based
vaccines for cancer and infectious diseases.
[0064] In the examples set forth below, 17% of the total analogs
screened (which fit the heteroclicity rules disclosed herein) were
heteroclitic (16/95). This is significant for two reasons: first,
the efficiency of detecting heteroclitics increased from 2.2% to
17% by employing analogs that follow the rules of heteroclitic
substitution; second, the number of peptides which need to be
synthesized is reduced dramatically from about a 100 analogs per
epitope to about I5 analogs per epitope, making the process cost
effective and amenable to high throughput. Through the application
of the heteroclitic substitution rules of the invention, the
efficiency of generating heteroclitic analogs was increased nearly
100 to 1000-fold, from 0.2% (4 identified from screening of 233
CEA.691 and MAGE3.112 analogs) to 33% (3 identified by screening of
9 predicted analogs). The latter frequency may be a gross
underestimate since only 4 of 6 analogs showing potential
heteroclitic activity in initial assays were subjected to further
analysis.
[0065] Previous studies showed that modulation of T cell responses
by heteroclitic analogs involved TCR contact residues (Byrne, et
al., J. Immunol. 51:682 (1984), McMichael, et al., K. England. J.
Med. 309:13 (1983), Zugel, et al., J. Immunol. 161:1705 (1998),
Rivoltini, et al., Cancer Research 59:301 (1999)), but the present
study did not find this. For example, for the CEA.691 epitope, the
TCR contact residue is position 8, while heteroclicity was observed
with analog substitutions at positions 3 and 5. While not intending
to be bound by any theory, alteration of MHC binding may be a
mechanism. Binding analyses performed on the analogs indicated that
there is an alteration in MHC binding for the better or worse in a
majority of cases (80%). Out of the 13 analogs which were tested
for HLA-A2 binding, ten analogs had alteration in MHC binding, with
six analogs binding better than wildtype peptides and four analogs
that bound worse than wildtype, but still generated a substantially
increased biological response. Some studies modify primary MHC
anchor residues in order to increase MHC binding (this approach has
been used by some groups to generate analogs (Pfeiffer, et al., J.
Exp. Med. 181:1569 (1995), Valmori, et al., J. Immunol.
160:1750-1758 (1998), Parkhurst, et al., J. Immunol. 157:2539
(1996)). Increased biological responses without changing primary
TCR contact residues or primary MHC anchor residues was observed in
this study. Since increased responses were mediated with alteration
in MHC binding, it is postulated that the effect may be mediated by
changing secondary anchor positions. More evidence supporting this
comes from the finding that heteroclitic substitutions occur at odd
numbered positions (3, 5, 7) in the middle of the peptide. All
these positions 3, 5, and 7 have been shown to be secondary anchor
positions for binding to the HLA-A2 molecule (Ruppert, et al., Cell
74:929 (1993), Madden, Annu. Rev. Immunol. 13:587-622 (1995)).
[0066] Two of these positions (3 and 7) have been shown to be
secondary anchor positions for binding to HLA-A2.1 molecule by
several groups (Ruppert, et al., Cell 74:929 (1993), Madden, Annu.
Rev. Immunol. 13:587-622 (1995)). Alteration of such secondary
anchor positions can translate into T cell recognition differences
(Valmori, et al., J. Immunol. 160:1750 (1998); Davis, et al., Annu.
Rev. Immunol. 16:523 (1998)), however in these studies T cell
recognition differences were associated with changes in MHC binding
and no rules were defined for the kinds of amino acid substitutions
involved in obtaining heteroclicity. The mechanism by which such a
translation from changing secondary anchors to change in T cell
recognition takes place is currently unclear. However, some models
suggest that changes in the way residues at secondary anchor
positions engage the MHC may lead to alteration in the orientation
or increased flexibility of TCR contact residues, resulting in
enhancement of the binding of these analogs to the TCR (Kersh, et
al., J. Exp. Med. 184:1259 (1996), Evavold, et al., J. Immunol.
148:347 (1992), Alam, et al., Immunity 10:227 (1999), Hampl, et
al., Immunity 7:379-85 (1997)). Also, some previous studies implied
that modulation of T cell responses by heteroclitic analogs
directly involve main TCR contact residues (Zaremba, et al., Cancer
Research 57:4570 (1997), Loftus, et al., Cancer Research 58:2433
(1998), Dressel, et al., J. Immunol. 159:4943 (1997)). This
finding, however, is not corroborated by the current systematic
analysis. The enhanced T cell recognition against analogs
identified in the present study is not likely due to increases in
MHC binding capacity, though increased binding is likely to play an
important role in the case of analogs in which primary anchor
positions have been optimized. The present study suggests that
heteroclitic analogs are most likely generated by subtle
alterations in conformation rather than by gross alterations of TCR
or MHC binding capacity.
[0067] Differential regulation of production of Th1 or Th2
cytokines was not observed. Instead, the present data suggested
that the heteroclitic analogs increased the production of both Th1
and Th2 responses, although the magnitude and kinetics of the
increase may be different. In fact, some groups (Nicholson, et al.,
Int. Immunol. 12 (2):205-13 (2000), Parkhurst, et al., J. Immunol.
157:2539 (1996)) have recently reported such overall stimulation by
peptide analogs. This is attributable to a stronger TCR signal
induced by analogs, though the mechanism of such overall
stimulation remains to be elucidated.
[0068] The efficacy of heteroclitic analogs in vivo using relevant
tumor models or models in which tolerance to self antigens exists
is evaluated. Accordingly, it is found that immunization with
heteroclitic analogs is a more effective and efficient strategy for
vaccination against tumors where raising effective CTLs has so far
proved to be a challenge.
[0069] To summarize, in a set of experiments, applicants have
identified heteroclitic analogs of a number of different
HLA-A2.1-restricted CTL epitopes of cancer and viral origin. The
relevant wildtype epitopes are shown in Table 1. All these epitopes
have been shown to be immunogenic in our earlier reports
(Kawashima, et al., Human Immunology 59:1-14 (1998), Ishioka, et
al., J. Immunol. 162 (7):3915-25 (1999)). In initial experiments,
the antigenicity of 233 analogs of the CEA.691 and MAGE3.112 CTL
epitopes was investigated. The nature of the four heteroclitic
analogs identified suggested that heteroclitic substitutions
involved conservative substitutions at positions 3, 5 and 7. This
hypothesis, was tested in a subsequent study involving three
additional epitopes MAGE2.157, HIVPol.476, and HBVPol.455. All of
the heteroclitic analogs thus identified conformed to the rules
proposed, namely that heteroclitic analogs were associated with
conservative or semi-conservative substitutions at positions 3, 5
and/or 7.
[0070] To more closely mimic the clinical application of
heteroclitic analogs in cancer immunotherapy, the murine epitope,
p53.261 was also modified. A partial state of T cell tolerance has
been reported for this epitope (Theobald, et al., Proc. Natl. Acad.
Sci. 92:11993-11997 (1995), Theobald, et al., J. Exp. Med., 185
(5):833-841 (1997)). Four out of nine predicted p53.261 analogs
were found to induce stronger analog-specific CTL responses in vivo
compared to the CTL responses induced by the native peptide. More
significantly, when the cross-reactivity of the CTL raised by
immunization with heteroclitic analogs was analyzed, three p53.261
analogs induced CTL which responded vigorously against the native
p53.261 epitope. Finally, the relevance of these findings for human
CTL was addressed by demonstrating that heteroclitic analogs of the
MAGE3.112 epitope are immunogenic for human T cells in vitro. The
resulting CTL can recognize wildtype naturally processed antigen in
the form of tumor cell lines.
[0071] The studies presented herein demonstrate that heteroclicity
is a global phenomenon, as heteroclitic analogs were identified for
all the epitopes studied. In addition, the present application
shows that it is possible to detect heteroclitic analogs both in
clonal T cell populations (as has been described earlier studies)
as well as in bulk T cell populations following in vivo
immunization. Moreover, it is demonstrated herein that
heteroclicity (both in the HLA A2.1 system as well as for other
Class I supermotifs) is associated with discrete structural
features which allow rational prediction of heteroclicity.
[0072] It is demonstrated, further that p53.261 heteroclitic
analogs induce CTLs with higher avidity and also induced these
cells in greater numbers (precursor frequency) than those induced
with wildtype peptide; heteroclitic CTL induction in vivo, and its
application to breaking T cell tolerance is demonstrated.
[0073] The heteroclitic analogs were effective in raising bulk
populations of specific T cells following in vivo immunization.
Polyclonal responses that bear TCR from multiple TCR genes, are
more efficacious in resolving disease states in a clinical setting.
Finally, the ability to generate high precursor frequencies of CTL
possessing strong cross-reactive avidity against wildtype epitope
is important in instances where effective CTL responses against
epitopes, normally tolerant to the immune system, are required.
[0074] In another set of experiments, applicants identified
heteroclitic analogs of the B7 superfamily epitope MAGE2.170 (shown
in Table 1). Like A2 heteroclitic epitopes, heteroclitic analogs of
the B7 superfamily epitope could be generated by introducing
substitutions at an odd-number position in the middle of the
peptide (position 7). The nature of the substitutions for the
MAGE2.170 epitope were either conservative/semi-conservative (the
Y.fwdarw.H and Y.fwdarw.M substitutions) or non-conservative (the
Y.fwdarw.E, Y.fwdarw.G, and Y.fwdarw.D substitutions) compared to
the native residue (Table 5). Thus, the observation that
non-conservative substitutions can result in heteroclitic analogs
for the MAGE2.170 CTL epitope indicate a partially overlapping
substitution pattern than that observed with A2 superfamily
epitopes.
2. Definitions
[0075] With regard to a particular amino acid sequence, an
"epitope" is a set of amino acid residues which is involved in
recognition by a particular immunoglobulin, or in the context of T
cells, those residues necessary for recognition by T cell receptor
proteins when presented in the context of an HLA encoded by the
Major Histocompatibility Complex (MHC). In an immune system
setting, in vitro or in vivo, an epitope is the collective features
of a molecule, such as primary, secondary and tertiary peptide
structure, and charge, that together form a site recognized by an
immunoglobulin, T cell receptor or HLA molecule. Throughout this
disclosure epitope and peptide are often used interchangeably. It
is to be appreciated, however, that isolated or purified protein or
peptide molecules larger than and comprising an epitope of the
invention are still within the invention.
[0076] A "Class I epitope" refers to a peptide that binds to a
Class I HLA molecule. As described herein, a Class I epitope is
typically about 8 to about 13 amino acids in length. Binding to the
HLA molecule is primarily controlled by two primary anchor
residues, one of which is at the C-terminus of the epitope and the
other of which is at positions 2 or 3. Binding may be aided also by
one or more secondary anchor residues. For the convenience of the
reader, various primary HLA Class I binding anchors are set forth
in Table 3. The pattern of anchors is referred to as a "motif." A
"supermotif" is a peptide binding specificity shared by HLA
molecules encoded by two or more HLA alleles. Preferably, a
supermotif-bearing peptide is recognized with high or intermediate
affinity (as defined herein) by two or more HLA antigens. Examples
of Class I supermotifs include, e.g., A1, A2, A3, A24, B7, B27,
B44, B58 and B62.
[0077] Throughout this disclosure, "binding data" results are often
expressed in terms of "IC.sub.50's." IC.sub.50 is the concentration
of peptide in a binding assay at which 50% inhibition of binding of
a reference peptide is observed. Given the conditions in which the
assays are run (i.e., limiting HLA proteins and labeled peptide
concentrations), these values approximate Kd values. Assays for
determining binding are described in detail, e.g., in PCT
publications WO 94/20127 and WO 94/03205, incorporated herein by
reference. It should be noted that IC.sub.50 values can change,
often dramatically, if the assay conditions are varied, and
depending on the particular reagents used (e.g., HLA preparation,
etc.). For example, excessive concentrations of HLA molecules will
increase the apparent measured IC.sub.50 of a given ligand.
Alternatively, binding is expressed relative to a reference
peptide. Although as a particular assay becomes more, or less,
sensitive, the IC.sub.50's of the peptides tested may change
somewhat, the binding relative to the reference peptide will not
significantly change. For example, in an assay run under conditions
such that the IC.sub.50 of the reference peptide increases 10-fold,
the IC.sub.50 values of the test peptides will also shift
approximately 10-fold. Therefore, to avoid ambiguities, the
assessment of whether a peptide is a good, intermediate, weak, or
negative binder is generally based on its IC.sub.50, relative to
the IC.sub.50 of a standard peptide. Binding may also be determined
using other assay systems known in the art.
[0078] The designation of a residue position in an epitope as the
"carboxyl or C-terminus" refers to the residue position at the end
of the epitope which is nearest to the carboxyl terminus of a
peptide, which is designated using conventional nomenclature as
defined below. The "C-terminus" of the epitope may or may not
actually correspond to the end of the peptide or polypeptide.
[0079] The designation of a residue position in an epitope as
"N-terminus" or "amino-terminal position" refers to the residue
position at the end of the epitope which is nearest to the
N-terminus of a peptide, which is designated using conventional
nomenclature as defined below. The "N-terminus" of the epitope may
or may not actually correspond to the end of the peptide or
polypeptide.
[0080] A "computer" or "computer system" generally includes: a
processor; at least one information storage/retrieval apparatus
such as, for example, a hard drive, a disk drive or a tape drive;
at least one input apparatus such as, for example, a keyboard, a
mouse, a touch screen, or a microphone; and display structure.
Additionally, the computer may include a communication channel in
communication with a network. Such a computer may include more or
less than what is listed above.
[0081] As used herein amino acids that are "conserved" or
"conservative," and "semi-conserved" or "semi-conservative," and
"non-conserved" or "non-conservative" are defined in accordance
with Preparation B and set forth in Table 2.
[0082] As used herein, "high affinity" with respect to HLA Class I
molecules is defined as binding with an IC.sub.50, or K.sub.D
value, of 50 nM or less; "intermediate affinity" is binding with an
IC.sub.50 or K.sub.D value of between about 50 and about 500 nM.
"High affinity" with respect to binding to HLA Class II molecules
is defined as binding with an IC.sub.50 or K.sub.D value of 100 nM
or less; "intermediate affinity" is binding with an IC.sub.50 or
K.sub.D value of between about 100 and about 1000 nM.
[0083] An "immunogenic peptide" or "peptide epitope" is a peptide
that comprises an allele-specific motif or supermotif such that the
peptide will bind an HLA molecule and induce a CTL and/or HTL
response. Thus, immunogenic peptides of the invention are capable
of binding to an appropriate HLA molecule and thereafter inducing a
cytotoxic T cell response, or a helper T cell response, to the
antigen from which the immunogenic peptide is derived.
[0084] The phrases "isolated" or "biologically pure" refer to
material that is substantially or essentially free from components
which normally accompany the material as it is found in its native
state. Thus, isolated peptides in accordance with the invention
preferably do not contain materials normally associated with the
peptides in their in situ environment.
[0085] A "PanDR binding peptide" is a member of a family of
molecules that binds more that one HLA Class II DR molecule (e.g.,
PADRE.TM. peptide, Epimmune Inc., San Diego, Calif.). The pattern
that defines the PADRE.TM. family of molecules can be thought of as
an HLA Class II supermotif. Peptides comprising the pattern found
in PADRE.TM. molecules bind to most HLA-DR molecules and stimulate
in vitro and in vivo human helper T lymphocyte (HTL) responses.
[0086] "Pharmaceutically acceptable" refers to a generally
non-toxic, inert, and/or physiologically compatible
composition.
3. Peptides of the Invention
[0087] Peptides in accordance with the invention can be prepared
synthetically, by recombinant DNA technology or chemical synthesis,
or from natural sources such as native tumors or pathogenic
organisms. Peptide epitopes may be synthesized individually or as
polyepitopic peptides. Although the peptide will preferably be
substantially free of other naturally occurring host cell proteins
and fragments thereof, in some embodiments the peptides may be
synthetically conjugated to native fragments or particles.
[0088] HLA Class I peptides are well known in the art and are
defined as peptides that bind to MHC Class I molecules. The
peptides in accordance with the invention can be a variety of
lengths, and either in their neutral (uncharged) forms or in forms
which are salts. The peptides in accordance with the invention are
either free of modifications such as glycosylation, side chain
oxidation, or phosphorylation; or they contain these modifications,
subject to the condition that modifications do not destroy the
biological activity of the peptides as described herein.
[0089] Class I epitopes that serve as the corresponding "wildtype"
can be derived from any proteinaceous source. For example, the
Class I peptides can be derived from viral antigens,
tumor-associated antigens, parasitic antigens, bacterial antigens
or fungal antigens. In some preferred aspects of the invention, the
Class I peptide(s) are derived from antigens for which a the immune
system of a subject has developed a tolerance, i.e., a specific
immunologic nonresponsiveness induced by prior exposure to an
antigen.
[0090] Thus, heteroclitic analogs based on a number of potential
target epitopes can be used in the present invention. Examples of
suitable tumor-associated antigens include prostate specific
antigens (PSA), melanoma antigens MAGE 1, MAGE 2, MAGE 3, MAGE-11,
MAGE-A10, as well as BAGE, GAGE, RAGE, MAGE-C1, LAGE-1, CAG-3, DAM,
MUC1, MUC2, MUC18, NY-ESO-1, MUM-1, CDK4, BRCA2, NY-LU-1, NY-LU-7,
NY-LU-12, CASP8, RAS, KIAA-2-5, SCCs, p53, p73, CEA, Her 2/neu,
Melan-A, gp100, tyrosinase, TRP2, gp75/TRP1, kallikrein,
prostate-specific membrane antigen (PSM), prostatic acid
phosphatase (PAP), prostate-specific antigen (PSA), PT1-1,
.beta.-catenin, PRAME, Telomerase, FAK, cyclin D1 protein, NOEY2,
EGF-R, SART-1, CAPB, HPVE7, p15, Folate receptor CDC27, PAGE-1, and
PAGE-4. Examples of suitable infectious disease-associated antigens
include hepatitis B core and surface antigens (HBVc, HBVs),
hepatitis C antigens, Epstein-Barr virus antigens, human
immunodeficiency virus (HIV) antigens and human papilloma virus
(HPV) antigens, Mycobacterium tuberculosis and Chlamydia. Examples
of suitable fungal antigens include those derived from Candida
albicans, Cryptococcus neoformans, Coccidoides spp., Histoplasma
spp, and Aspergillus fumigatis. Examples of suitable protozoal
parasitic antigens include those derived from Plasmodium spp.,
including P. falciparum, Trypanosoma spp., Schistosoma spp.,
Leishmania spp and the like.
[0091] The epitopes that may be used as wildtype sequences to which
the rules of the invention are applied to construct corresponding
heteroclitic analogs can be found corresponding to any Class I
epitope. For any desired antigen, such as those set forth above,
the motif associated with a particular Class I allele can be used
as a guide to determine the positions in the amino acid sequence of
the antigen wherein such an epitope would reside. This
determination can be done visually or, preferably, using computer
technology and associated software. Thus, for example, by
recognition of the A3 supermotif as containing, for example, valine
in position 2 and arginine at the C-terminus, the amino acid
sequence of any desired antigen can be surveyed for epitopes
bearing this motif. That epitope can then be modified according to
the rules set forth in the present invention to obtain the desired
analogs.
[0092] When possible, it may be desirable to optimize HLA Class I
binding epitopes of the invention, such as can be used in a
polyepitopic construct, to a length of about 8 to about 13 amino
acid residues, often 8 to 11, preferably 9 to 10. Preferably, the
peptide epitopes are commensurate in size with endogenously
processed pathogen-derived peptides or tumor cell peptides that are
bound to the relevant HLA molecules, however, the identification
and preparation of peptides that comprise epitopes of the invention
can also be carried out using the techniques described herein.
[0093] In alternative embodiments, epitopes of the invention can be
linked as a polyepitopic peptide, or as a minigene that encodes a
polyepitopic peptide.
[0094] In another embodiment, it is preferred to identify native
peptide regions that contain a high concentration of Class I
epitopes and/or Class II epitopes. Such a sequence is generally
selected on the basis that it contains the greatest number of
epitopes per amino acid length. It is to be appreciated that
epitopes can be present in a nested or overlapping manner, e.g., a
10 amino acid long peptide could contain two 9 amino acid long
epitopes and one 10 amino acid long epitope; upon intracellular
processing, each epitope can be exposed and bound by an HLA
molecule upon administration of such a peptide. This larger,
preferably multi-epitopic, peptide can be generated synthetically,
recombinantly, or via cleavage from the native source.
[0095] The peptides of the invention can be prepared in a wide
variety of ways. For the preferred relatively short size, the
peptides can be synthesized in solution or on a solid support in
accordance with conventional techniques. Various automatic
synthesizers are commercially available and can be used in
accordance with known protocols. (See, for example, Stewart &
Young, SOLID PHASE PEPTIDE SYNTHESIS, 2D. ED., Pierce Chemical Co.,
1984). Further, individual peptide epitopes can be joined using
chemical ligation to produce larger peptides that are still within
the bounds of the invention.
[0096] Alternatively, recombinant DNA technology can be employed
wherein a nucleotide sequence which encodes an immunogenic peptide
of interest is inserted into an expression vector, transformed or
transfected into an appropriate host cell and cultivated under
conditions suitable for expression. These procedures are generally
known in the art, as described generally in Sambrook, et al.,
MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Press,
Cold Spring Harbor, N.Y. (1989). Thus, recombinant polypeptides
which comprise one or more peptide sequences of the invention can
be used to present the appropriate T cell epitope.
[0097] The nucleotide coding sequence for peptide epitopes of the
preferred lengths contemplated herein can be synthesized by
chemical techniques, for example, the phosphotriester method of
Matteucci, et al., J. Am. Chem. Soc. 103:3185 (1981). Peptide
analogs can be made simply by substituting the appropriate and
desired nucleic acid base(s) for those that encode the native
peptide sequence; exemplary nucleic acid substitutions are those
that encode an amino acid defined by the motifs/supermotifs herein.
The coding sequence can then be provided with appropriate linkers
and ligated into expression vectors commonly available in the art,
and the vectors used to transform suitable hosts to produce the
desired fusion protein. A number of such vectors and suitable host
systems are now available. For expression of the fusion proteins,
the coding sequence will be provided with operably linked start and
stop codons, promoter and terminator regions and usually a
replication system to provide an expression vector for expression
in the desired cellular host. For example, promoter sequences
compatible with bacterial hosts are provided in plasmids containing
convenient restriction sites for insertion of the desired coding
sequence. The resulting expression vectors are transformed into
suitable bacterial hosts. Of course, yeast, insect or mammalian
cell hosts may also be used, employing suitable vectors and control
sequences.
[0098] Analogs of the present invention may include peptides
containing substitutions to modify the physical property (e.g.,
stability or solubility) of the resulting peptide. For example,
peptides may be modified by the substitution of a cysteine (C) with
.alpha.-amino butyric acid. Due to its chemical nature, cysteine
has the propensity to form disulfide bridges and sufficiently alter
the peptide structurally so as to reduce binding capacity.
Substituting .alpha.-amino butyric acid for C not only alleviates
this problem, but actually improves binding and crossbinding
capability in certain instances. Substitution of cysteine with
.alpha.-amino butyric acid may occur at any residue of a peptide
epitope, i.e. at either anchor or non-anchor positions.
[0099] Modified peptides that have various amino acid mimetics or
unnatural amino acids are particularly useful, as they tend to
manifest increased stability in vivo. Such analogs may also possess
improved shelf-life or manufacturing properties. More specifically,
non-critical amino acids need not be limited to those naturally
occurring in proteins, such as L-.alpha.-amino acids, or their
D-isomers, but may include non-natural amino acids as well, such as
amino acids mimetics, e.g. D- or L-naphylalanine; D- or
L-phenylglycine; D- or L-2-thieneylalanine; D- or L-1,-2,3-, or
4-pyreneylalanine; D- or L-3 thieneylalanine; D- or
L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)-alanine; D- or
L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)-phenylglycine;
D-(trifluoromethyl)-phenylglycine;
D-(trifluoromethyl)-phenylalanine; D-.rho.-fluorophenylalanine; D-
or L-.rho.-biphenylphenylalanine; D- or
L-.rho.-methoxybiphenylphenylalanine; D- or
L-2-indole(alkyl)alanines; and, D- or L-alkylalanines, where the
alkyl group can be a substituted or unsubstituted methyl, ethyl,
propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl,
iso-pentyl, or a non-acidic amino acids. Aromatic rings of a
nonnatural amino acid include, e.g., thiazolyl, thiophenyl,
pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl
aromatic rings.
[0100] Peptide stability can be assayed in a number of ways. For
instance, peptidases and various biological media, such as human
plasma and serum, have been used to test stability. See, e.g.,
Verhoef, et al., Eur. J. Drug Metab. Pharmacokinetics 11:291
(1986). Half life of the peptides of the present invention is
conveniently determined using a 25% human serum (v/v) assay. The
protocol is generally as follows: Pooled human serum (Type AB,
non-heat inactivated) is delipidated by centrifugation before use.
The serum is then diluted to 25% with RPMI-1640 or another suitable
tissue culture medium. At predetermined time intervals, a small
amount of reaction solution is removed and added to either 6%
aqueous trichloroacetic acid (TCA) or ethanol. The cloudy reaction
sample is cooled (4.degree. C.) for 15 minutes and then spun to
pellet the precipitated serum proteins. The presence of the
peptides is then determined by reversed-phase HPLC using
stability-specific chromatography conditions.
4. Class I Motifs
[0101] In the past few years, evidence has accumulated to
demonstrate that a large fraction of HLA Class I molecules can be
classified into a relatively few supertypes, each characterized by
largely overlapping peptide binding repertoires, and consensus
structures of the main peptide binding pockets. Thus, peptides of
the present invention are identified by any one of several
HLA-specific amino acid motifs (see, e.g., Tables 3-4), or if the
presence of the motif corresponds to the ability to bind several
allele-specific HLA antigens, a supermotif. The HLA molecules that
bind to peptides that possess a particular amino acid supermotif
are collectively referred to as an HLA "supertype."
[0102] For the convenience of the reader, the peptide motifs and
supermotifs described below, and summarized in Tables 3-4, provide
guidance for the identification and use of peptide epitopes in
accordance with the invention. This will permit identification of
candidate wildtype epitopes corresponding to various Class I motifs
different from those illustrated in the examples below or epitopes
bearing those illustrated below but in different antigens in order
to apply the rules set forth herein to construct analogs.
[0103] Heteroclitic analogs can be designed according to the
methods of the invention from a peptide, without regard to the
motif or supermotif to which the peptide belongs. The primary
anchor residues of the HLA Class I peptide epitope supermotifs and
motifs delineated below are summarized in Table 3. The HLA Class I
motifs set out in Table 4 are those most particularly relevant to
the invention claimed here. Allele-specific HLA molecules that
comprise HLA Class I supertype families are listed in Table 5. In
some cases, peptide epitopes may be listed in both a motif and a
supermotif. The relationship of a particular motif and respective
supermotif is indicated in the description of the individual
motifs.
[0104] i. HLA-A1 Supermotif
[0105] The HLA-A1 supermotif is characterized by the presence in
peptide ligands of a small (T or S) or hydrophobic (L, I, V, or M)
primary anchor residue in position 2, and an aromatic (Y, F, or W)
primary anchor residue at the C-terminal position of the epitope.
The corresponding family of HLA molecules that bind to the A1
supermotif (i.e., the HLA-A1 supertype) is comprised of at least
A*0101, A*2601, A*2602, A*2501, and A*3201 (see, e.g., DiBrino, M.
et al., J. Immunol. 151:5930, 1993; DiBrino, M. et al., J. Immunol.
152:620, 1994; Kondo, A. et al., Immunogenetics 45:249, 1997).
Other allele-specific HLA molecules predicted to be members of the
A1 superfamily are shown in Table 5.
[0106] ii. HLA-A2 Supermotif
[0107] Primary anchor specificities for allele-specific HLA-A2.1
molecules (see, e.g., Falk et al., Nature 351:290-296, 1991; Hunt
et al., Science 255:1261-1263, 1992; Parker et al., J. Immunol.
149:3580-3587, 1992; Ruppert et al., Cell 74:929-937, 1993) and
cross-reactive binding among HLA-A2 and -A28 molecules have been
described. (See, e.g., Fruci et al., Human Immunol. 38:187-192,
1993; Tanigaki et al., Human Immunol. 39:155-162, 1994; Del Guercio
et al., J. Immunol. 154:685-693, 1995; Kast et al., J. Immunol.
152:3904-3912, 1994 for reviews of relevant data). These primary
anchor residues define the HLA-A2 supermotif; which presence in
peptide ligands corresponds to the ability to bind several
different HLA-A2 and -A28 molecules. The HLA-A2 supermotif
comprises peptide ligands with L, I, V, M, A, T, or Q as a primary
anchor residue at position 2 and L, I, V, M, A, or T as a primary
anchor residue at the C-terminal position of the epitope.
[0108] The corresponding family of HLA molecules (i.e., the HLA-A2
supertype that binds these peptides) is comprised of at least:
A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0209,
A*0214, A*6802, and A*6901. Other allele-specific HLA molecules
predicted to be members of the A2 superfamily are shown in Table
5.
[0109] iii. HLA-A3 Supermotif
[0110] The HLA-A3 supermotif is characterized by the presence in
peptide ligands of A, L, I, V, M, S, or, T as a primary anchor at
position 2, and a positively charged residue, R or K, at the
C-terminal position of the epitope, e.g., in position 9 of 9-mers
(see, e.g., Sidney et al., Hum. Immunol. 45:79, 1996). Exemplary
members of the corresponding family of HLA molecules (the HLA-A3
supertype) that bind the A3 supermotif include at least A*0301,
A*1101, A*3101, A*3301, and A*6801. Other allele-specific HLA
molecules predicted to be members of the A3 supertype are shown in
Table 5.
[0111] iv. HLA-A24 Supermotif
[0112] The HLA-A24 supermotif is characterized by the presence in
peptide ligands of an aromatic (F, W, or Y) or hydrophobic
aliphatic (L, I, V, M, or T) residue as a primary anchor in
position 2, and Y, F, W, L, I, or M as primary anchor at the
C-terminal position of the epitope (see, e.g., Sette and Sidney,
Immunogenetics, in press, 1999). The corresponding family of HLA
molecules that bind to the A24 supermotif (i.e., the A24 supertype)
includes at least A*2402, A*3001, and A*2301. Other allele-specific
HLA molecules predicted to be members of the A24 supertype are
shown in Table 5.
[0113] V. HLA-B7 Supermotif
[0114] The HLA-B7 supermotif is characterized by peptides bearing
proline in position 2 as a primary anchor, and a hydrophobic or
aliphatic amino acid (L, I, V, M, A, F, W, or Y) as the primary
anchor at the C-terminal position of the epitope. The corresponding
family of HLA molecules that bind the B7 supermotif (i.e., the
HLA-B7 supertype) is comprised of at least twenty six HLA-B
proteins including: B*0702, B*0703, B*0704, B*0705, B*1508, B*3501,
B*3502, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101,
B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502,
B*5601, B*5602, B*6701, and B*7801 (see, e.g., Sidney, et al., J.
Immunol. 154:247, 1995; Barber, et al., Curr. Biol. 5:179, 1995;
Hill, et al., Nature 360:434, 1992; Rammensee, et al.,
Immunogenetics 41:178, 1995 for reviews of relevant data). Other
allele-specific HLA molecules predicted to be members of the B7
supertype are shown in Table 5.
[0115] vi. HLA-B27 Supermotif
[0116] The HLA-B27 supermotif is characterized by the presence in
peptide ligands of a positively charged (R, H, or K) residue as a
primary anchor at position 2, and a hydrophobic (F, Y, L, W, M, I,
A, or V) residue as a primary anchor at the C-terminal position of
the epitope (see, e.g., Sidney and Sette, Immunogenetics, in press,
1999). Exemplary members of the corresponding family of HLA
molecules that bind to the B27 supermotif (i.e., the B27 supertype)
include at least B*1401, B*1402, B*1509, B*2702, B*2703, B*2704,
B*2705, B*2706, B*3801, B*3901, B*3902, and B*7301. Other
allele-specific HLA molecules predicted to be members of the B27
supertype are shown in Table 5.
[0117] vii. HLA-B44 Supermotif
[0118] The HLA-B44 supermotif is characterized by the presence in
peptide ligands of negatively charged (D or E) residues as a
primary anchor in position 2, and hydrophobic residues (F, W, Y, L,
I, M, V, or A) as a primary anchor at the C-terminal position of
the epitope (see, e.g., Sidney et al., Immunol. Today 17:261,
1996). Exemplary members of the corresponding family of HLA
molecules that bind to the B44 supermotif (i.e., the B44 supertype)
include at least: B*1801, B*1802, B*3701, B*4001, B*4002, B*4006,
B*4402, B*4403, and B*4006.
[0119] viii. HLA-B58 Supermotif
[0120] The HLA-B58 supermotif is characterized by the presence in
peptide ligands of a small aliphatic residue (A, S, or T) as a
primary anchor residue at position 2, and an aromatic or
hydrophobic residue (F, W, Y, L, I, V, M, or A) as a primary anchor
residue at the C-terminal position of the epitope (see, e.g.,
Sidney and Sette, Immunogenetics, in press, 1999 for reviews of
relevant data). Exemplary members of the corresponding family of
HLA molecules that bind to the B58 supermotif (i.e., the B58
supertype) include at least: B*1516, B*1517, B*5701, B*5702, and
B*5801. Other allele-specific HLA molecules predicted to be members
of the B58 supertype are shown in Table 5.
[0121] ix. HLA-B62 Supermotif
[0122] The HLA-B62 supermotif is characterized by the presence in
peptide ligands of the polar aliphatic residue Q or a hydrophobic
aliphatic residue (L, V, M, I, or P) as a primary anchor in
position 2, and a hydrophobic residue (F, W, Y, M, I, V, L, or A)
as a primary anchor at the C-terminal position of the epitope (see,
e.g., Sidney and Sette, Immunogenetics, in press, 1999). Exemplary
members of the corresponding family of HLA molecules that bind to
the B62 supermotif (i.e., the B62 supertype) include at least:
B*1501, B*1502, B*1513, and B5201. Other allele-specific HLA
molecules predicted to be members of the B62 supertype are shown in
Table 5.
[0123] x. HLA-A1 Motif
[0124] The HLA-A1 motif is characterized by the presence in peptide
ligands of T, S, or M as a primary anchor residue at position 2 and
the presence of Y as a primary anchor residue at the C-terminal
position of the epitope. An alternative allele-specific A1 motif is
characterized by a primary anchor residue at position 3 rather than
position 2. This motif is characterized by the presence of D, E, A,
or S as a primary anchor residue in position 3, and a Y as a
primary anchor residue at the C-terminal position of the epitope
(see, e.g., DiBrino et al., J. Immunol., 152:620, 1994; Kondo et
al., Immunogenetics 45:249, 1997; and Kubo et al., J. Immunol.
152:3913, 1994 for reviews of relevant data).
[0125] xi. HLA-A*0201 Motif
[0126] An HLA-A2*0201 motif was determined to be characterized by
the presence in peptide ligands of L or M as a primary anchor
residue in position 2, and L or V as a primary anchor residue at
the C-terminal position of a 9-residue peptide (see, e.g., Falk et
al., Nature 351:290-296, 1991) and was further found to comprise an
I at position 2 and I or A at the C-terminal position of a nine
amino acid peptide (see, e.g., Hunt et al., Science 255:1261-1263,
Mar. 6, 1992; Parker et al., J. Immunol. 149:3580-3587, 1992). The
A*0201 allele-specific motif has also been defined by the present
inventors to additionally comprise V, A, T, or Q as a primary
anchor residue at position 2, and M or T as a primary anchor
residue at the C-terminal position of the epitope (see, e.g., Kast
et al, J. Immunol. 152:3904-3912, 1994). Thus, the HLA-A*0201 motif
comprises peptide ligands with L, I, V, M, A, T, or Q as primary
anchor residues at position 2 and L, I, V, M, A, or T as a primary
anchor residue at the C-terminal position of the epitope. The
preferred and tolerated residues that characterize the primary
anchor positions of the HLA-A*0201 motif are identical to the
residues describing the A2 supermotif.
[0127] xii. HLA-A3 Motif
[0128] The HLA-A3 motif is characterized by the presence in peptide
ligands of L, M, V, I, S, A, T, F, C, G, or D as a primary anchor
residue at position 2, and the presence of K, Y, R, H, F, or A as a
primary anchor residue at the C-terminal position of the epitope
(see, e.g., DiBrino et al., Proc. Natl. Acad. Sci. USA 90:1508,
1993; and Kubo et al., J. Immunol. 152:3913-3924, 1994).
[0129] xiii. HLA-A11 Motif
[0130] The HLA-A11 motif is characterized by the presence in
peptide ligands of V, T, M, L, I, S, A, G, N, C, D, or F as a
primary anchor residue in position 2, and K, R, Y, or H as a
primary anchor residue at the C-terminal position of the epitope
(see, e.g., Zhang et al., Proc. Natl. Acad. Sci. USA 90:2217-2221,
1993; and Kubo et al., J. Immunol. 152:3913-3924, 1994).
[0131] xiv. HLA-A24 Motif
[0132] The HLA-A24 motif is characterized by the presence in
peptide ligands of Y, F, W, or M as a primary anchor residue in
position 2, and F, L, I, or W as a primary anchor residue at the
C-terminal position of the epitope (see, e.g., Kondo et al., J.
Immunol. 155:4307-4312, 1995; and Kubo et al., J. Immunol.
152:3913-3924, 1994).
5. Assays to Detect T-Cell Responses
[0133] Once heteroclitic analogs of the invention are synthesized,
they can be tested for the ability to elicit a T-cell response. The
preparation and evaluation of motif-bearing peptides such as
heteroclitic analogs are described in PCT publications WO 94/20127
and WO 94/03205. Briefly, peptides comprising epitopes from a
particular antigen are synthesized and tested for their ability to
bind to the appropriate HLA proteins. These assays may involve
evaluating the binding of a peptide of the invention to purified
HLA Class I molecules in relation to the binding of a
radioiodinated reference peptide. Alternatively, cells expressing
empty Class I molecules (i.e. lacking peptide therein) may be
evaluated for peptide binding by immunofluorescent staining and
flow microfluorimetry. Other assays that may be used to evaluate
peptide binding include peptide-dependent Class I assembly assays
and/or the inhibition of CTL recognition by peptide competition.
Those peptides that bind to the Class I molecule, typically with an
affinity of 500 nM or less, are further evaluated for their ability
to serve as targets for CTLs derived from infected or immunized
individuals, as well as for their capacity to induce primary in
vitro or in vivo CTL responses that can give rise to CTL
populations capable of reacting with selected target cells
associated with a disease.
[0134] Conventional assays utilized to detect T cell responses
include proliferation assays, lymphokine secretion assays, direct
cytotoxicity assays, and limiting dilution assays. Such assays are
useful in comparing the induction of immune responses by
heteroclitic analog peptides to response induced by
non-heteroclitic analogs Class I peptides (e.g., from which the
heterocloitic analog sequence was based). For example,
antigen-presenting cells that have been incubated with a peptide
can be assayed for the ability to induce CTL responses in responder
cell populations. Antigen-presenting cells can be normal cells such
as peripheral blood mononuclear cells or dendritic cells.
Alternatively, mutant non-human mammalian cell lines that are
deficient in their ability to load Class I molecules with
internally processed peptides and that have been transfected with
the appropriate human Class I gene, may be used to test for the
capacity of the peptide to induce in vitro primary CTL
responses.
[0135] Peripheral blood mononuclear cells (PBMCs) may be used as
the responder cell source of CTL precursors. The appropriate
antigen-presenting cells are incubated with peptide, after which
the peptide-loaded antigen-presenting cells are then incubated with
the responder cell population under optimized culture conditions.
Positive CTL activation can be determined by assaying the culture
for the presence of CTLs that kill radio-labeled target cells, both
specific peptide-pulsed targets as well as target cells expressing
endogenously processed forms of the antigen from which the peptide
sequence was derived.
[0136] Additionally, a method has been devised which allows direct
quantification of antigen-specific T cells by staining with
Fluorescein-labelled HLA tetrameric complexes (Altman, J. D. et
al., Proc. Natl. Acad. Sci. USA 90:10330, 1993; Altman, J. D. et
al., Science 274:94, 1996). Other relatively recent technical
developments include staining for intracellular lymphokines, and
interferon-.gamma. release assays or Elispot assays. Tetramer
staining, intracellular lymphokine staining and Elispot assays all
appear to be at least 10-fold more sensitive than more conventional
assays (Lalvani, A. et al., J. Exp. Med. 186:859, 1997; Dunbar, P.
R. et al., Curr. Biol. 8:413, 1998; Murali-Krishna, K. et al.,
Immunity 8:177, 1998).
[0137] If desired, HTL activation may also be assessed using such
techniques known to those in the art such as T cell proliferation
and secretion of lymphokines, e.g. IL-2 (see, e.g. Alexander, et
al., Immunity 1:751-761, 1994).
[0138] Alternatively, immunization of HLA transgenic mice can be
used to determine immunogenicity of peptide epitopes. Several
transgenic mouse models including mice with human A2.1, A11 (which
can additionally be used to analyze HLA-A3 epitopes), and B7
alleles have been characterized and others (e.g., transgenic mice
for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse
models have also been developed. Additional transgenic mouse models
with other HLA alleles may be generated as necessary. The mice may
be immunized with peptides emulsified in Incomplete Freund's
Adjuvant and the resulting T cells tested for their capacity to
recognize peptide-pulsed target cells and target cells transfected
with appropriate genes. CTL responses may be analyzed using
cytotoxicity assays described above. Similarly, HTL responses may
be analyzed using such assays as T cell proliferation or secretion
of lymphokines.
[0139] Heteroclitic analogs of the invention often induce both Th1
and Th2 cytokine responses. Therefore, one method to compare a
heteroclitic candidate with a preselected Class I peptide is to
test the induction of Th1 and Th2 cytokines. The preselected Class
I peptide will typically be a peptide from which the heteroclitic
analog is derived, or if such a peptide does not exist, a Class I
peptide with the highest similarity to the candidate. Heteroclitic
analogs of the invention typically induce both Th1 and Th2 cytokine
responses, but at a level greatly enhanced compared to the Class I
peptide from which the analog was derived. For example, a given
heteroclitic analog will stimulate an equivalent level of Th1 or
Th2 cytokine (50 to 100 pg/ml) at a 10-fold or lower dose compared
to the wildtype peptide from which the analog was derived.
Additionally, where the Class I peptide induces only, or mainly,
either a Th1 or Th2 response, a heteroclitic analog may induce both
Th1 and Th2 responses. Th1 cytokines include, e.g., IFN.gamma.,
IL-2 and IL-3. Th2 cytokines include, e.g., IL-4, IL-5, IL-6 and
IL-10. Production of cytokines can be measured, for example, using
ELISA or other immunological quantitation methods. See, e.g.,
McKinney, et al. Journal of Immunological Methods 237:105-117
(2000).
6. Use of Peptide Epitopes as Diagnostic Agents and for Evaluating
Immune Responses
[0140] In one embodiment of the invention, heteroclitic analog
peptides as described herein are used as reagents to evaluate an
immune response. The immune response to be evaluated is induced by
using as an immunogen any agent that may result in the induction of
antigen-specific CTLs or HTLs that recognize and bind to the
peptide epitope(s) to be employed as the reagent. The peptide
reagent need not be used as the immunogen. Assay systems that are
used for such an analysis include relatively recent technical
developments such as tetramers, staining for intracellular
lymphokines and interferon release assays, or Elispot assays.
[0141] For example, peptides of the invention are used in tetramer
staining assays to assess peripheral blood mononuclear cells for
the presence of antigen-specific CTLs following exposure to a tumor
cell antigen or an immunogen. The HLA-tetrameric complex is used to
directly visualize antigen-specific CTLs (see, e.g., Ogg et al.,
Science 279:2103-2106, 1998; and Altman et al., Science 174:94-96,
1996) and determine the frequency of the antigen-specific CTL
population in a sample of peripheral blood mononuclear cells. A
tetramer reagent using a peptide of the invention is generated as
follows: A peptide that binds to an HLA molecule is refolded in the
presence of the corresponding HLA heavy chain and
.beta..sub.2-microglobulin to generate a trimolecular complex. The
complex is biotinylated at the carboxyl terminal end of the heavy
chain at a site that was previously engineered into the protein.
Tetramer formation is then induced by the addition of streptavidin.
By means of fluorescently labeled streptavidin, the tetramer can be
used to stain antigen-specific cells. The cells can then be
identified, for example, by flow cytometry. Such an analysis may be
used for diagnostic or prognostic purposes. Cells identified by the
procedure can also be used for therapeutic purposes.
[0142] Peptides of the invention are also used as reagents to
evaluate immune recall responses (see, e.g., Bertoni, et al., J.
Clin. Invest. 100:503-513, 1997 and Penna, et al., J. Exp. Med.
174:1565-1570, 1991). For example, patient PBMC samples from
individuals with cancer are analyzed for the presence of
antigen-specific CTLs or HTLs using specific peptides. A blood
sample containing mononuclear cells can be evaluated by cultivating
the PBMCs and stimulating the cells with a peptide of the
invention. After an appropriate cultivation period, the expanded
cell population can be analyzed, for example, for CTL or for HTL
activity.
[0143] The peptides are also used as reagents to evaluate the
efficacy of a vaccine. PBMCs obtained from a patient vaccinated
with an immunogen are analyzed using, for example, either of the
methods described above. The patient is HLA typed, and peptide
epitope reagents that recognize the allele-specific molecules
present in that patient are selected for the analysis. The
immunogenicity of the vaccine is indicated by the presence of
epitope-specific CTLs and/or HTLs in the PBMC sample.
[0144] The peptides of the invention are also used to make
antibodies, using techniques well known in the art (see, e.g.
CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY; and Antibodies A
Laboratory Manual, Harlow and Lane, Cold Spring Harbor Laboratory
Press, 1989), which may be useful as reagents to diagnose or
monitor cancer. Such antibodies include those that recognize a
peptide in the context of an HLA molecule, i.e., antibodies that
bind to a peptide-MHC complex.
7. Vaccine Compositions
[0145] Vaccines and methods of preparing vaccines that contain an
immunogenically effective amount of one or more peptides as
described herein are further embodiments of the invention. Once
appropriately immunogenic epitopes have been defined, they can be
sorted and delivered by various means, herein referred to as
"vaccine" compositions. Such vaccine compositions can include, for
example, lipopeptides (e.g., Vitiello, A. et al., J. Clin. Invest.
95:341, 1995), peptide compositions encapsulated in
poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g.,
Eldridge, et al., Molec. Immunol. 28:287-294, 1991: Alonso et al.,
Vaccine 12:299-306, 1994; Jones et al., Vaccine 13:675-681, 1995),
peptide compositions contained in immune stimulating complexes
(ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875, 1990; Hu
et al., Clin Exp Immunol. 113:235-243, 1998), multiple antigen
peptide systems (MAPs) (see e.g., Tam, J. P., Proc. Natl. Acad.
Sci. USA. 85:5409-5413, 1988; Tam, J. P., J. Immunol. Methods
196:17-32, 1996), peptides formulated as multivalent peptides;
peptides for use in ballistic delivery systems, typically
crystallized peptides, viral delivery vectors (Perkus, M. E. et
al., In: Concepts in vaccine development, Kaufmann, S. H. E., ed.,
p. 379, 1996; Chakrabarti, S. et al., Nature 320:535, 1986; Hu, S.
L. et al., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS
Bio/Technology 4:790, 1986; Top, F. H. et al., J. Infect. Dis.
124:148, 1971; Chanda, P. K. et al., Virology 175:535, 1990),
particles of viral or synthetic origin (e.g., Kofler, N. et al., J.
Immunol. Methods. 192:25, 1996; Eldridge, J. H. et al., Sem.
Hematol. 30:16, 1993; Falo, L. D., Jr. et al., Nature Med. 7:649,
1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A.
Annu. Rev. Immunol. 4:369, 1986; Gupta, R. K. et al., Vaccine
11:293, 1993), liposomes (Reddy, R. et al., J. Immunol. 148:1585,
1992; Rock, K. L., Immunol. Today 17:131, 1996), or, naked or
particle absorbed cDNA (Ulmer, J. B. et al., Science 259:1745,
1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., Vaccine
11:957, 1993; Shiver, J. W. et al., In: Concepts in vaccine
development, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B.,
and Berzofsky, J. A., Annu. Rev. Immunol. 12:923, 1994 and
Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993). Toxin-targeted
delivery technologies, also known as receptor mediated targeting,
such as those of Avant Immunotherapeutics, Inc. (Needham, Mass.)
may also be used.
[0146] Vaccines of the invention include nucleic acid-mediated
modalities. DNA or RNA encoding one or more of the peptides of the
invention can also be administered to a patient. This approach is
described, for instance, in Wolff et. al., Science 247:1465 (1990)
as well as U.S. Pat. Nos. 5,580,859; 5,589,466; 5,804,566;
5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail
below. Examples of DNA-based delivery technologies include "naked
DNA", facilitated (bupivicaine, polymers, peptide-mediated)
delivery, cationic lipid complexes, and particle-mediated ("gene
gun") or pressure-mediated delivery (see, e.g., U.S. Pat. No.
5,922,687).
[0147] For therapeutic or prophylactic immunization purposes, the
peptides of the invention can also be expressed by viral or
bacterial vectors. Examples of expression vectors include
attenuated viral hosts, such as vaccinia or fowlpox. As an example
of this approach, vaccinia virus is used as a vector to express
nucleotide sequences that encode the peptides of the invention.
Upon introduction into a host bearing a tumor, the recombinant
vaccinia virus expresses the immunogenic peptide, and thereby
elicits a host CTL and/or HTL response. Vaccinia vectors and
methods useful in immunization protocols are described in, e.g.,
U.S. Pat. No. 4,722,848. Another vector is BCG (Bacille Calmette
Guerin). BCG vectors are described in Stover et al., Nature
351:456-460 (1991). A wide variety of other vectors useful for
therapeutic administration or immunization of the peptides of the
invention, e.g. adeno and adeno-associated virus vectors,
retroviral vectors, Salmonella typhi vectors, detoxified anthrax
toxin vectors, and the like, will be apparent to those skilled in
the art from the description herein.
[0148] Furthermore, vaccines in accordance with the invention
encompass compositions of one or more of the claimed peptides. A
peptide can be present in a vaccine individually. Alternatively,
the peptide can exist as a homopolymer comprising multiple copies
of the same peptide, or as a heteropolymer of various peptides.
Polymers have the advantage of increased immunological reaction
and, where different peptide epitopes are used to make up the
polymer, the additional ability to induce antibodies and/or CTLs
that react with different antigenic determinants of the pathogenic
organism or tumor-related peptide targeted for an immune response.
The composition can be a naturally occurring region of an antigen
or can be prepared, e.g., recombinantly or by chemical
synthesis.
[0149] Carriers that can be used with vaccines of the invention are
well known in the art, and include, e.g., thyroglobulin, albumins
such as human serum albumin, tetanus toxoid, polyamino acids such
as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B
virus core protein, and the like. The vaccines can contain a
physiologically tolerable (i.e., acceptable) diluent such as water,
or saline, preferably phosphate buffered saline. The vaccines also
typically include an adjuvant. Adjuvants such as incomplete
Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum
are examples of materials well known in the art. Additionally, as
disclosed herein, CTL responses can be primed by conjugating
peptides of the invention to lipids, such as
tripalmitoyl-S-glycerylcysteinlyseryl-serine (P.sub.3CSS).
[0150] Upon immunization with a peptide composition in accordance
with the invention, via injection, aerosol, oral, transdermal,
transmucosal, intrapleural, intrathecal, or other suitable routes,
the immune system of the host responds to the vaccine by producing
large amounts of CTLs and/or HTLs specific for the desired antigen.
Consequently, the host becomes at least partially immune to later
infection, or at least partially resistant to developing an ongoing
chronic infection, or derives at least some therapeutic benefit
when the antigen was tumor-associated.
[0151] In some embodiments, it may be desirable to combine the
heteroclitic analog peptides of the invention with components that
induce or facilitate neutralizing antibody and or helper T cell
responses to the target antigen of interest. A preferred embodiment
of such a composition comprises Class I and Class II epitopes in
accordance with the invention. An alternative embodiment of such a
composition comprises a Class I and/or Class II epitope in
accordance with the invention, along with a pan-DR binding peptide
such as PADRE.TM. (Epimmune, San Diego, Calif.) molecule
(described, for example, in U.S. Pat. No. 5,736,142).
[0152] A vaccine of the invention can also include
antigen-presenting cells (APC), such as dendritic cells (DC), as a
vehicle to present peptides of the invention. Vaccine compositions
can be created in vitro, following dendritic cell mobilization and
harvesting, whereby loading of dendritic cells occurs in vitro. For
example, dendritic cells are transfected, e.g., with a minigene in
accordance with the invention, or are pulsed with peptides. The
dendritic cell can then be administered to a patient to elicit
immune responses in vivo.
[0153] Vaccine compositions, either DNA- or peptide-based, can also
be administered in vivo in combination with dendritic cell
mobilization whereby loading of dendritic cells occurs in vivo.
[0154] Antigenic peptides are used to elicit a CTL and/or HTL
response ex vivo, as well. The resulting CTL or HTL cells, can be
used to treat tumors in patients that do not respond to other
conventional forms of therapy, or will not respond to a therapeutic
vaccine peptide or nucleic acid in accordance with the invention.
Ex vivo CTL or HTL responses to a particular tumor-associated
antigen are induced by incubating in tissue culture the patient's,
or genetically compatible, CTL or HTL precursor cells together with
a source of antigen-presenting cells, such as dendritic cells, and
the appropriate immunogenic peptide. After an appropriate
incubation time (typically about 7-28 days), in which the precursor
cells are activated and expanded into effector cells, the cells are
infused back into the patient, where they will destroy (CTL) or
facilitate destruction (HTL) of their specific target cell (an
infected cell or a tumor cell). Transfected dendritic cells may
also be used as antigen presenting cells.
[0155] The vaccine compositions of the invention can also be used
in combination with other treatments used for cancer, including use
in combination with immune adjuvants such as IL-2, IL-12, GM-CSF,
and the like.
[0156] Preferably, the following principles are utilized when
selecting an array of epitopes for inclusion in a polyepitopic
composition for use in a vaccine, or for selecting discrete
epitopes to be included in a vaccine and/or to be encoded by
nucleic acids such as a minigene. It is preferred that each of the
following principles are balanced in order to make the selection.
The multiple epitopes to be incorporated in a given vaccine
composition may be, but need not be, contiguous in sequence in the
native antigen from which the epitopes are derived.
[0157] 1) Epitopes are selected which, upon administration, mimic
immune responses that have been observed to be correlated with
tumor clearance. For HLA Class I, this includes 3-4 epitopes that
come from at least one tumor-associated antigen (TAA). For HLA
Class II, a similar rationale is employed; again 3-4 epitopes are
selected from at least one TAA (see e.g., Rosenberg et al, Science
278:1447-1450). Epitopes from one TAA may be used in combination
with epitopes from one or more additional TAAs to produce a vaccine
that targets tumors with varying expression patterns of
frequently-expressed TAAs.
[0158] 2) Epitopes are selected that have the requisite binding
affinity established to be correlated with immunogenicity: for HLA
Class I an IC.sub.50 of 500 nM or less, often 200 nM or less; and
for Class II an IC.sub.50 of 1000 nM or less.
[0159] 3) Sufficient supermotif bearing-peptides, or a sufficient
array of allele-specific motif-bearing peptides, are selected to
give broad population coverage. For example, it is preferable to
have at least 80% population coverage. A Monte Carlo analysis, a
statistical evaluation known in the art, can be employed to assess
the breadth, or redundancy of, population coverage.
[0160] 4) When selecting epitopes from cancer-related antigens it
is often useful to select analogs because the patient may have
developed tolerance to the native epitope. When selecting epitopes
for infectious disease-related antigens, it is preferable to select
either native or analoged epitopes.
[0161] 5) Of particular relevance are epitopes referred to as
"nested epitopes." Nested epitopes occur where at least two
epitopes overlap in a given peptide sequence. A nested peptide
sequence can comprise both HLA Class I and HLA Class II epitopes.
When providing nested epitopes, a general objective is to provide
the greatest number of epitopes per sequence. Thus, an aspect is to
avoid providing a peptide that is any longer than the amino
terminus of the amino terminal epitope and the carboxyl terminus of
the carboxyl terminal epitope in the peptide. When providing a
multi-epitopic sequence, such as a sequence comprising nested
epitopes, it is generally important to screen the sequence in order
to insure that it does not have pathological or other deleterious
biological properties.
[0162] 6) If a polyepitopic protein is created, or when creating a
minigene, an objective is to generate the smallest peptide that
encompasses the epitopes of interest. This principle is similar, if
not the same as that employed when selecting a peptide comprising
nested epitopes. However, with an artificial polyepitopic peptide,
the size minimization objective is balanced against the need to
integrate any spacer sequences between epitopes in the polyepitopic
protein. Spacer amino acid residues can, for example, be introduced
to avoid junctional epitopes (an epitope recognized by the immune
system, not present in the target antigen, and only created by the
man-made juxtaposition of epitopes), or to facilitate cleavage
between epitopes and thereby enhance epitope presentation.
Junctional epitopes are generally to be avoided because the
recipient may generate an immune response to that non-native
epitope. Of particular concern is a junctional epitope that is a
"dominant epitope." A dominant epitope may lead to such a zealous
response that immune responses to other epitopes are diminished or
suppressed.
8. Minigene Vaccines
[0163] A number of different approaches are available which allow
simultaneous delivery of multiple epitopes. Nucleic acids encoding
the peptides of the invention are a particularly useful embodiment
of the invention. Epitopes for inclusion in a minigene are
preferably selected according to the guidelines set forth in the
previous section. A preferred means of administering nucleic acids
encoding the peptides of the invention uses minigene constructs
encoding a peptide comprising one or multiple epitopes of the
invention.
[0164] The use of multi-epitope minigenes is described below and
in, e.g., co-pending application U.S. Ser. No. 09/311,784; Ishioka
et al., J. Immunol. 162:3915-3925, 1999; An, L. and Whitton, J. L.,
J. Virol. 71:2292, 1997; Thomson, S. A. et al., J. Immunol.
157:822, 1996; Whitton, J. L. et al., J. Virol. 67:348, 1993;
Hanke, R. et al., Vaccine 16:426, 1998. For example, a
multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing
epitopes (e.g., PSA, PSM, PAP, and hK2) derived from multiple
regions of a TAA, a pan_DR binding peptide such as the PADRE.TM.
universal helper T cell epitope, and an endoplasmic
reticulum-translocating signal sequence can be engineered. A
vaccine may also comprise epitopes that are derived from other
TAAs.
[0165] The immunogenicity of a multi-epitopic minigene can be
tested in transgenic mice to evaluate the magnitude of CTL
induction responses against the epitopes tested. Further, the
immunogenicity of DNA-encoded epitopes in vivo can be correlated
with the in vitro responses of specific CTL lines against target
cells transfected with the DNA plasmid. Thus, these experiments can
show that the minigene serves to both: 1.) generate a CTL response
and 2.) that the induced CTLs recognized cells expressing the
encoded epitopes.
[0166] For example, to create a DNA sequence encoding the selected
epitopes (minigene) for expression in human cells, the amino acid
sequences of the epitopes may be reverse translated. A human codon
usage table can be used to guide the codon choice for each amino
acid. These epitope-encoding DNA sequences may be directly
adjoined, so that when translated, a continuous polypeptide
sequence is created. To optimize expression and/or immunogenicity,
additional elements can be incorporated into the minigene design.
Examples of amino acid sequences that can be reverse translated and
included in the minigene sequence include: HLA Class I epitopes,
HLA Class II epitopes, a ubiquitination signal sequence, and/or an
endoplasmic reticulum targeting signal. In addition, HLA
presentation of CTL and HTL epitopes may be improved by including
synthetic (e.g. poly-alanine) or naturally-occurring flanking
sequences adjacent to the CTL or HTL epitopes; these larger
peptides comprising the epitope(s) are within the scope of the
invention.
[0167] The minigene sequence may be converted to DNA by assembling
oligonucleotides that encode the plus and minus strands of the
minigene. Overlapping oligonucleotides (30-100 bases long) may be
synthesized, phosphorylated, purified and annealed under
appropriate conditions using well known techniques. The ends of the
oligonucleotides can be joined, for example, using T4 DNA ligase.
This synthetic minigene, encoding the epitope polypeptide, can then
be cloned into a desired expression vector.
[0168] Standard regulatory sequences well known to those of skill
in the art are preferably included in the vector to ensure
expression in the target cells. Several vector elements are
desirable: a promoter with a down-stream cloning site for minigene
insertion; a polyadenylation signal for efficient transcription
termination; an E. coli origin of replication; and an E. coli
selectable marker (e.g. ampicillin or kanamycin resistance).
Numerous promoters can be used for this purpose, e.g., the human
cytomegalovirus (hCMV) promoter. See, e.g., U.S. Pat. Nos.
5,580,859 and 5,589,466 for other suitable promoter sequences.
[0169] Additional vector modifications may be desired to optimize
minigene expression and immunogenicity. In some cases, introns are
required for efficient gene expression, and one or more synthetic
or naturally-occurring introns could be incorporated into the
transcribed region of the minigene. The inclusion of mRNA
stabilization sequences and sequences for replication in mammalian
cells may also be considered for increasing minigene
expression.
[0170] Once an expression vector is selected, the minigene is
cloned into the polylinker region downstream of the promoter. This
plasmid is transformed into an appropriate E. coli strain, and DNA
is prepared using standard techniques. The orientation and DNA
sequence of the minigene, as well as all other elements included in
the vector, are confirmed using restriction mapping and DNA
sequence analysis. Bacterial cells harboring the correct plasmid
can be stored as a master cell bank and a working cell bank.
[0171] In addition, immunostimulatory sequences (ISSs or CpGs)
appear to play a role in the immunogenicity of DNA vaccines. These
sequences may be included in the vector, outside the minigene
coding sequence, if desired to enhance immunogenicity.
[0172] In some embodiments, a bi-cistronic expression vector which
allows production of both the minigene-encoded epitopes and a
second protein (included to enhance or decrease immunogenicity) can
be used. Examples of proteins or polypeptides that could
beneficially enhance the immune response if co-expressed include
cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules
(e.g., LeIF), costimulatory molecules, or for HTL responses, pan-DR
binding proteins (e.g., PADRE.TM., Epimmune, San Diego, Calif.).
Helper (HTL) epitopes can be joined to intracellular targeting
signals and expressed separately from expressed CTL epitopes; this
allows direction of the HTL epitopes to a cell compartment
different than that of the CTL epitopes. If required, this could
facilitate more efficient entry of HTL epitopes into the HLA Class
II pathway, thereby improving HTL induction. In contrast to HTL or
CTL induction, specifically decreasing the immune response by
co-expression of immunosuppressive molecules (e.g. TGF-.beta.) may
be beneficial in certain diseases.
[0173] Therapeutic quantities of plasmid DNA can be produced for
example, by fermentation in E. coli, followed by purification.
Aliquots from the working cell bank are used to inoculate growth
medium, and grown to saturation in shaker flasks or a bioreactor
according to well known techniques. Plasmid DNA can be purified
using standard bioseparation technologies such as solid phase
anion-exchange resins supplied by QIAGEN, Inc. (Valencia, Calif.).
If required, supercoiled DNA can be isolated from the open circular
and linear forms using gel electrophoresis or other methods.
[0174] Purified plasmid DNA can be prepared for injection using a
variety of formulations. The simplest of these is reconstitution of
lyophilized DNA in sterile phosphate-buffered saline (PBS). This
approach, known as "naked DNA," is currently being used for
intramuscular (IM) administration in clinical trials. To maximize
the immunotherapeutic effects of minigene DNA vaccines, an
alternative method for formulating purified plasmid DNA may be
desirable. A variety of methods have been described, and new
techniques may become available. Cationic lipids, glycolipids, and
fusogenic liposomes can also be used in the formulation (see, e.g.,
as described by WO 93/24640; Mannino & Gould-Fogerite,
BioTechniques 6 (7): 682 (1988); U.S. Pat. No. 5,279,833; WO
91/06309; and Felgner, et al., Proc. Nat'l Acad. Sci. USA 84:7413
(1987). In addition, peptides and compounds referred to
collectively as protective, interactive, non-condensing compounds
(PINC) could also be complexed to purified plasmid DNA to influence
variables such as stability, intramuscular dispersion, or
trafficking to specific organs or cell types.
[0175] Target cell sensitization can be used as a functional assay
for expression and HLA Class I presentation of minigene-encoded CTL
epitopes. For example, the plasmid DNA is introduced into a
mammalian cell line that is suitable as a target for standard CTL
chromium release assays. The transfection method used will be
dependent on the final formulation. Electroporation can be used for
"naked" DNA, whereas cationic lipids allow direct in vitro
transfection. A plasmid expressing green fluorescent protein (GFP)
can be co-transfected to allow enrichment of transfected cells
using fluorescence activated cell sorting (FACS). These cells are
then chromium-51 (.sup.51Cr) labeled and used as target cells for
epitope-specific CTL lines; cytolysis, detected by .sup.51Cr
release, indicates both production of, and HLA presentation of,
minigene-encoded CTL epitopes. Expression of HTL epitopes may be
evaluated in an analogous manner using assays to assess HTL
activity.
[0176] In vivo immunogenicity is a second approach for functional
testing of minigene DNA formulations. Transgenic mice expressing
appropriate human HLA proteins are immunized with the DNA product.
The dose and route of administration can be formulation dependent
(e.g., IM for DNA in PBS, intraperitoneal (IP) for lipid-complexed
DNA). Twenty-one days after immunization, splenocytes are harvested
and restimulated for one week in the presence of peptides encoding
each epitope being tested. Thereafter, for CTL effector cells,
assays are conducted for cytolysis of peptide-loaded,
.sup.51Cr-labeled target cells using standard techniques. Lysis of
target cells that were sensitized by HLA loaded with peptide
epitopes, corresponding to minigene-encoded epitopes, demonstrates
DNA vaccine function for in vivo induction of CTLs. Immunogenicity
of HTL epitopes is evaluated in transgenic mice in an analogous
manner.
[0177] Alternatively, the nucleic acids can be administered
intradermally, e.g. by injection or ballistic delivery as
described, for instance, in U.S. Pat. No. 5,204,253. Using this
technique, particles comprised solely of DNA are administered. In a
further alternative embodiment, DNA can be adhered to particles,
such as gold particles.
[0178] Minigenes can also be delivered using other bacterial or
viral delivery systems well known in the art, e.g., an expression
construct encoding epitopes of the invention can be incorporated
into a viral vector such as vaccinia.
9. Combinations of CTL Peptides with Helper Peptides
[0179] Vaccine compositions comprising the peptides of the present
invention can be modified to provide desired attributes, such as
improved serum half-life, or to enhance immunogenicity.
[0180] For instance, the ability of a peptide to induce CTL
activity can be enhanced by linking the peptide to a sequence which
contains at least one epitope that is capable of inducing a T
helper cell response. The use of T helper epitopes in conjunction
with CTL epitopes to enhance immunogenicity is illustrated, for
example, in the co-pending applications U.S. Ser. No. 08/820,360,
U.S. Ser. No. 08/197,484, and U.S. Ser. No. 08/464,234.
[0181] Although a CTL peptide can be directly linked to a T helper
peptide, often CTL epitope/HTL epitope conjugates are linked by a
spacer molecule. The spacer is typically comprised of relatively
small, neutral molecules, such as amino acids or amino acid
mimetics, which are substantially uncharged under physiological
conditions. The spacers are typically selected from, e.g., Ala,
Gly, or other neutral spacers of nonpolar amino acids or neutral
polar amino acids. It will be understood that the optionally
present spacer need not be comprised of the same residues and thus
may be a hetero- or homo-oligomer. When present, the spacer will
usually be at least one or two residues, more usually three to six
residues and sometimes 10 or more residues. The CTL peptide epitope
can be linked to the T helper peptide epitope either directly or
via a spacer either at the amino or carboxy terminus of the CTL
peptide. The amino terminus of either the immunogenic peptide or
the T helper peptide may be acylated.
[0182] In certain embodiments, the T helper peptide is one that is
recognized by T helper cells present in the majority of the
population. This can be accomplished by selecting amino acid
sequences that bind to many, most, or all of the HLA Class II
molecules. These are known as "loosely HLA-restricted" or
"promiscuous" T helper sequences. Examples of peptides that are
promiscuous include sequences from antigens such as tetanus toxoid
at positions 830-843 (QYIKANSKFIGITE) (SEQ ID NO:32), Plasmodium
falciparum circumsporozoite (CS) protein at positions 378-398
(DIEKKIAKMEKASSVFNVVNS) (SEQ ID NO:33), and Streptococcus 18 kD
protein at positions 116 (GAVDSILGGVATYGAA) (SEQ ID NO:34). Other
examples include peptides bearing a DR 1-4-7 supermotif, or either
of the DR3 motifs.
[0183] Alternatively, it is possible to prepare synthetic peptides
capable of stimulating T helper lymphocytes, in a loosely
HLA-restricted fashion, using amino acid sequences not found in
nature (see, e.g., PCT publication WO 95/07707). These synthetic
compounds called Pan-DR-binding epitopes (e.g., PADRE.TM.,
Epimmune, Inc., San Diego, Calif.) are designed to most preferrably
bind most HLA-DR (human HLA Class II) molecules. For instance, a
pan-DR-binding epitope peptide having the formula: aKXVAAWTLKAAa,
where "X" is either cyclohexylalanine (SEQ ID NO: 35),
phenylalanine (SEQ ID NO:36), or tyrosine (SEQ ID NO:37), and "a"
is either D-alanine or L-alanine, has been found to bind to most
HLA-DR alleles, and to stimulate the response of T helper
lymphocytes from most individuals, regardless of their HLA type. An
alternative of a pan-DR binding epitope comprises all "L" natural
amino acids and can be provided in the form of nucleic acids that
encode the epitope.
[0184] HTL peptide epitopes can also be modified to alter their
biological properties. For example, they can be modified to include
D-amino acids to increase their resistance to proteases and thus
extend their serum half life, or they can be conjugated to other
molecules such as lipids, proteins, carbohydrates, and the like to
increase their biological activity. For example, a T helper peptide
can be conjugated to one or more palmitic acid chains at either the
amino or carboxyl termini.
10. Combinations of CTL Peptides with T Cell Priming Agents
[0185] In some embodiments it may be desirable to include in the
pharmaceutical compositions of the invention at least one component
which primes cytotoxic T lymphocytes. Lipids have been identified
as agents capable of priming CTL in vivo against viral antigens.
For example, palmitic acid residues can be attached to the
.epsilon.- and .alpha.-amino groups of a lysine residue and then
linked, e.g., via one or more linking residues such as Gly,
Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The
lipidated peptide can then be administered either directly in a
micelle or particle, incorporated into a liposome, or emulsified in
an adjuvant, e.g., incomplete Freund's adjuvant. A preferred
immunogenic composition comprises palmitic acid attached to
.epsilon.- and .alpha.-amino groups of Lys, which is attached via
linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic
peptide.
[0186] As another example of lipid priming of CTL responses, E.
coli lipoproteins, such as
tripalmitoyl-S-glycerylcysteinlyseryl-serine (P.sub.3CSS) can be
used to prime virus specific CTL when covalently attached to an
appropriate peptide (see, e.g., Deres, et al., Nature 342:561,
1989). Peptides of the invention can be coupled to P.sub.3CSS, for
example, and the lipopeptide administered to an individual to
specifically prime a CTL response to the target antigen. Moreover,
because the induction of neutralizing antibodies can also be primed
with P.sub.3CSS-conjugated epitopes, two such compositions can be
combined to more effectively elicit both humoral and cell-mediated
responses.
[0187] CTL and/or HTL peptides can also be modified by the addition
of amino acids to the termini of a peptide to provide for ease of
linking peptides one to another, for coupling to a carrier support
or larger peptide, for modifying the physical or chemical
properties of the peptide or oligopeptide, or the like. Amino acids
such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or
the like, can be introduced at the C- or N-terminus of the peptide
or oligopeptide, particularly Class I peptides. However, it is to
be noted that modification at the carboxyl terminus of a CTL
epitope may, in some cases, alter binding characteristics of the
peptide. In addition, the peptide or oligopeptide sequences can
differ from the natural sequence by being modified by
terminal-NH.sub.2 acylation, e.g., by alkanoyl (C.sub.1-C.sub.20)
or thioglycolyl acetylation, terminal-carboxyl amidation, e.g.,
ammonia, methylamine, etc. In some instances these modifications
may provide sites for linking to a support or other molecule.
11. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL
Peptides
[0188] An embodiment of a vaccine composition in accordance with
the invention comprises ex vivo administration of a cocktail of
epitope-bearing peptides to PBMC, or isolated DC therefrom, from
the patient's blood. A pharmaceutical to facilitate harvesting of
DC can be used, such as Progenipoietin.TM. (Monsanto, St. Louis,
Mo.) or GM-CSF/IL-4. After pulsing the DC with peptides and prior
to reinfusion into patients, the DC are washed to remove unbound
peptides. In this embodiment, a vaccine comprises peptide-pulsed
DCs that present the pulsed peptide epitopes complexed with HLA
molecules on their surfaces.
[0189] The DC can be pulsed ex vivo with a cocktail of peptides,
some of which stimulate CTL response to one or more antigens of
interest. Optionally, a helper T cell peptide such as a PADRE.TM.
family molecule, can be included to facilitate the CTL
response.
12. Administration of Vaccines for Therapeutic or Prophylactic
Purposes
[0190] The peptides of the present invention and pharmaceutical and
vaccine compositions of the invention are typically used
therapeutically to treat cancer. Vaccine compositions containing
the peptides of the invention are typically administered to a
cancer patient who has a malignancy associated with expression of
one or more antigens. Alternatively, vaccine compositions can be
administered to an individual susceptible to, or otherwise at risk
for developing cancer.
[0191] In therapeutic applications, peptide and/or nucleic acid
compositions are administered to a patient in an amount sufficient
to elicit an effective CTL and/or HTL response to the tumor antigen
and to cure or at least partially arrest or slow symptoms and/or
complications. An amount adequate to accomplish this is defined as
"therapeutically effective dose." Amounts effective for this use
will depend on, e.g., the particular composition administered, the
manner of administration, the stage and severity of the disease
being treated, the weight and general state of health of the
patient, and the judgment of the prescribing physician.
[0192] As noted above, peptides comprising CTL and/or HTL epitopes
of the invention induce immune responses when presented by HLA
molecules and contacted with a CTL or HTL specific for an epitope
comprised by the peptide. The peptides (or DNA encoding them) can
be administered individually or as fusions of one or more peptide
sequences. The manner in which the peptide is contacted with the
CTL or HTL is not critical to the invention. For instance, the
peptide can be contacted with the CTL or HTL either in vivo or in
vitro. If the contacting occurs in vivo, the peptide itself can be
administered to the patient, or other vehicles, e.g., DNA vectors
encoding one or more peptides, viral vectors encoding the
peptide(s), liposomes and the like, can be used, as described
herein.
[0193] When the peptide is contacted in vitro, the vaccinating
agent can comprise a population of cells, e.g., peptide-pulsed
dendritic cells, or TAA-specific CTLs, which have been induced by
pulsing antigen-presenting cells in vitro with the peptide or by
transfecting antigen-presenting cells with a minigene of the
invention. Such a cell population is subsequently administered to a
patient in a therapeutically effective dose.
[0194] For therapeutic use, administration should generally begin
at the first diagnosis of cancer. This is followed by boosting
doses until at least symptoms are substantially abated and for a
period thereafter. The embodiment of the vaccine composition (i.e.,
including, but not limited to embodiments such as peptide
cocktails, polyepitopic polypeptides, minigenes, or TAA-specific
CTLs or pulsed dendritic cells) delivered to the patient may vary
according to the stage of the disease or the patient's health
status. For example, a vaccine comprising TAA-specific CTLs may be
more efficacious in killing tumor cells in patients with advanced
disease than alternative embodiments.
[0195] The vaccine compositions of the invention may also be used
therapeutically in combination with treatments such as surgery. An
example is a situation in which a patient has undergone surgery to
remove a primary tumor and the vaccine is then used to slow or
prevent recurrence and/or metastasis.
[0196] Where susceptible individuals, e.g., individuals who may be
diagnosed as being genetically pre-disposed to developing a
prostate tumor, are identified prior to diagnosis of cancer, the
composition can be targeted to them, thus minimizing the need for
administration to a larger population.
[0197] The dosage for an initial therapeutic immunization generally
occurs in a unit dosage range where the lower value is about 1, 5,
50, 500, or 1,000 .mu.g and the higher value is about 10,000;
20,000; 30,000; or 50,000 .mu.g. Dosage values for a human
typically range from about 500 .mu.g to about 50,000 .mu.g per 70
kilogram patient. Initial doses followed by boosting doses at
established intervals, e.g., from four weeks to six months, may be
required, possibly for a prolonged period of time to effectively
treat a patient. Boosting dosages of between about 1.0 .mu.g to
about 50,000 .mu.g of peptide pursuant to a boosting regimen over
weeks to months may be administered depending upon the patient's
response and condition as determined by measuring the specific
activity of CTL and HTL obtained from the patient's blood.
[0198] Administration should continue until at least clinical
symptoms or laboratory tests indicate that the tumor has been
eliminated or that the tumor cell burden has been substantially
reduced and for a period thereafter. The dosages, routes of
administration, and dose schedules are adjusted in accordance with
methodologies known in the art.
[0199] In certain embodiments, peptides and compositions of the
present invention are employed in serious disease states, that is,
life-threatening or potentially life threatening situations. In
such cases, as a result of the minimal amounts of extraneous
substances and the relative nontoxic nature of the peptides in
preferred compositions of the invention, it is possible and may be
felt desirable by the treating physician to administer substantial
excesses of these peptide compositions relative to these stated
dosage amounts.
[0200] The vaccine compositions of the invention can also be used
as prophylactic agents. For example, the compositions can be
administered to individuals at risk of developing prostate cancer.
Generally the dosage for an initial prophylactic immunization
generally occurs in a unit dosage range where the lower value is
about 1, 5, 50, 500, or 1000 .mu.g and the higher value is about
10,000; 20,000; 30,000; or 50,000 .mu.g. Dosage values for a human
typically range from about 500 .mu.g to about 50,000 .mu.g per 70
kilogram patient. This is followed by boosting dosages of between
about 1.0 .mu.g to about 50,000 .mu.g of peptide administered at
defined intervals from about four weeks to six months after the
initial administration of vaccine. The immunogenicity of the
vaccine may be assessed by measuring the specific activity of CTL
and HTL obtained from a sample of the patient's blood.
[0201] The pharmaceutical compositions for therapeutic treatment
are intended for parenteral, topical, oral, intrathecal, or local
administration. Preferably, the pharmaceutical compositions are
administered parentally, e.g., intravenously, subcutaneously,
intradermally, or intramuscularly. Thus, the invention provides
compositions for parenteral administration which comprise a
solution of the immunogenic peptides dissolved or suspended in an
acceptable carrier, preferably an aqueous carrier. A variety of
aqueous carriers may be used, e.g., water, buffered water, 0.8%
saline, 0.3% glycine, hyaluronic acid and the like. These
compositions may be sterilized by conventional, well known
sterilization techniques, or may be sterile filtered. The resulting
aqueous solutions may be packaged for use as is, or lyophilized,
the lyophilized preparation being combined with a sterile solution
prior to administration. The compositions may contain
pharmaceutically acceptable auxiliary substances as required to
approximate physiological conditions, such as pH-adjusting and
buffering agents, tonicity adjusting agents, wetting agents,
preservatives, and the like, for example, sodium acetate, sodium
lactate, sodium chloride, potassium chloride, calcium chloride,
sorbitan monolaurate, triethanolamine oleate, etc.
[0202] The concentration of peptides of the invention in the
pharmaceutical formulations can vary widely, i.e., from less than
about 0.1%, usually at or at least about 2% to as much as 20% to
50% or more by weight, and will be selected primarily by fluid
volumes, viscosities, etc., in accordance with the particular mode
of administration selected.
[0203] A human unit dose form of the peptide composition is
typically included in a pharmaceutical composition that comprises a
human unit dose of an acceptable carrier, preferably an aqueous
carrier, and is administered in a volume of fluid that is known by
those of skill in the art to be used for administration of such
compositions to humans (see, e.g., Remington's Pharmaceutical
Sciences, 17.sup.th Edition, A. Gennaro, Editor, Mack Publishing
Co., Easton, Pa., 1985).
[0204] The peptides of the invention may also be administered via
liposomes, which serve to target the peptides to a particular
tissue, such as lymphoid tissue, or to target selectively to
infected cells, as well as to increase the half-life of the peptide
composition. Liposomes include emulsions, foams, micelles,
insoluble monolayers, liquid crystals, phospholipid dispersions,
lamellar layers and the like. In these preparations, the peptide to
be delivered is incorporated as part of a liposome, alone or in
conjunction with a molecule which binds to a receptor prevalent
among lymphoid cells, such as monoclonal antibodies which bind to
the CD45 antigen, or with other therapeutic or immunogenic
compositions. Thus, liposomes either filled or decorated with a
desired peptide of the invention can be directed to the site of
lymphoid cells, where the liposomes then deliver the peptide
compositions. Liposomes for use in accordance with the invention
are formed from standard vesicle-forming lipids, which generally
include neutral and negatively charged phospholipids and a sterol,
such as cholesterol. The selection of lipids is generally guided by
consideration of, e.g., liposome size, acid lability and stability
of the liposomes in the blood stream. A variety of methods are
available for preparing liposomes, as described in, e.g., Szoka, et
al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), and U.S. Pat. Nos.
4,235,871, 4,501,728, 4,837,028, and 5,019,369.
[0205] For targeting cells of the immune system, a ligand to be
incorporated into the liposome can include, e.g., antibodies or
fragments thereof specific for cell surface determinants of the
desired immune system cells. A liposome suspension containing a
peptide may be administered intravenously, locally, topically,
etc., in a dose which varies according to, inter alia, the manner
of administration, the peptide being delivered, and the stage of
the disease being treated.
[0206] For solid compositions, conventional nontoxic solid carriers
may be used which include, for example, pharmaceutical grades of
mannitol, lactose, starch, magnesium stearate, sodium saccharin,
talcum, cellulose, glucose, sucrose, magnesium carbonate, and the
like. For oral administration, a pharmaceutically acceptable
nontoxic composition is formed by incorporating any of the normally
employed excipients, such as those carriers previously listed, and
generally 10-95% of active ingredient, that is, one or more
peptides of the invention, and more preferably at a concentration
of 25%-75%.
[0207] For aerosol administration, the immunogenic peptides are
preferably supplied in finely divided form along with a surfactant
and propellant. Typical percentages of peptides are 0.01%-20% by
weight, preferably 1%-10%. The surfactant must, of course, be
nontoxic, and preferably soluble in the propellant. Representative
of such agents are the esters or partial esters of fatty acids
containing from 6 to 22 carbon atoms, such as caproic, octanoic,
lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic
acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
Mixed esters, such as mixed or natural glycerides may be employed.
The surfactant may constitute 0.1%-20% by weight of the
composition, preferably 0.25-5%. The balance of the composition is
ordinarily propellant. A carrier can also be included, as desired,
as with, e.g., lecithin for intranasal delivery.
13. Kits
[0208] The peptide and nucleic acid compositions of this invention
can be provided in kit form together with instructions for vaccine
administration. Typically the kit would include desired peptide
compositions in a container, preferably in unit dosage form and
instructions for administration. An alternative kit would include a
minigene construct with desired nucleic acids of the invention in a
container, preferably in unit dosage form together with
instructions for administration. Lymphokines such as IL-2 or IL-12
may also be included in the kit. Other kit components that may also
be desirable include, for example, a sterile syringe, booster
dosages, and other desired excipients.
[0209] Epitopes in accordance with the present invention were
successfully used to induce an immune response. Immune responses
with these epitopes have been induced by administering the epitopes
in various forms. The epitopes have been administered as peptides,
as nucleic acids, and as viral vectors comprising nucleic acids
that encode the epitope(s) of the invention. Upon administration of
peptide-based epitope forms, immune responses have been induced by
direct loading of an epitope onto an empty HLA molecule that is
expressed on a cell, and via internalization of the epitope and
processing via the HLA Class I pathway; in either event, the HLA
molecule expressing the epitope was then able to interact with and
induce a CTL response. Peptides can be delivered directly or using
such agents as liposomes. They can additionally be delivered using
ballistic delivery, in which the peptides are typically in a
crystalline form. When DNA is used to induce an immune response, it
is administered either as naked DNA, generally in a dose range of
approximately 1-5 mg, or via the ballistic "gene gun" delivery,
typically in a dose range of approximately 10-100 .mu.g. The DNA
can be delivered in a variety of conformations, e.g., linear,
circular etc. Various viral vectors have also successfully been
used that comprise nucleic acids which encode epitopes in
accordance with the invention.
[0210] Accordingly compositions in accordance with the invention
exist in several forms. Embodiments of each of these composition
forms in accordance with the invention have been successfully used
to induce an immune response.
[0211] One composition in accordance with the invention comprises a
plurality of peptides. This plurality or cocktail of peptides is
generally admixed with one or more pharmaceutically acceptable
excipients. The peptide cocktail can comprise multiple copies of
the same peptide or can comprise a mixture of peptides. The
peptides can be analogs of naturally occurring epitopes. The
peptides can comprise artificial amino acids and/or chemical
modifications such as addition of a surface active molecule, e.g.,
lipidation; acetylation, glycosylation, biotinylation,
phosphorylation etc. The peptides can be CTL or HTL epitopes. In a
preferred embodiment the peptide cocktail comprises a plurality of
different CTL epitopes and at least one HTL epitope. The HTL
epitope can be naturally or non-naturally (e.g., PADRE.RTM.,
Epimmune Inc., San Diego, Calif.). The number of distinct epitopes
in an embodiment of the invention is generally a whole unit integer
from one through one hundred fifty (e.g., 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,
43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,
60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,
77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,
94, 95, 96, 97, 98, 99, . . . , 150).
[0212] An additional embodiment of a composition in accordance with
the invention comprises a polypeptide multi-epitope construct,
i.e., a polyepitopic peptide. Polyepitopic peptides in accordance
with the invention are prepared by use of technologies well-known
in the art. By use of these known technologies, epitopes in
accordance with the invention are connected one to another. The
polyepitopic peptides can be linear or non-linear, e.g.,
multivalent. These polyepitopic constructs can comprise artificial
amino acids, spacing or spacer amino acids, flanking amino acids,
or chemical modifications between adjacent epitope units. The
polyepitopic construct can be a heteropolymer or a homopolymer. The
polyepitopic constructs generally comprise epitopes in a quantity
of any whole unit integer between 2-1.50 (e.g., 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,
59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, . . . , 150). The polyepitopic
construct can comprise CTL and/or HTL epitopes. One or more of the
epitopes in the construct can be modified, e.g., by addition of a
surface active material, e.g. a lipid, or chemically modified,
e.g., acetylation, etc. Moreover, bonds in the multiepitopic
construct can be other than peptide bonds, e.g., covalent bonds,
ester or ether bonds, disulfide bonds, hydrogen bonds, ionic bonds,
etc.
[0213] Alternatively, a composition in accordance with the
invention comprises construct which comprises a series, sequence,
stretch, etc., of amino acids that have homology to (i.e.,
corresponds to or is contiguous with) to a native sequence. This
stretch of amino acids comprises at least one subsequence of amino
acids that, if cleaved or isolated from the longer series of amino
acids, functions as an HLA Class I or HLA Class II epitope in
accordance with the invention. In this embodiment, the peptide
sequence is modified, so as to become a construct as defined
herein, by use of any number of techniques known or to be provided
in the art. The polyepitopic constructs can contain homology to a
native sequence in any whole unit integer increment from 70-100%
(e.g., 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or, 100
percent).
[0214] A further embodiment of a composition in accordance with the
invention is an antigen presenting cell that comprises one or more
epitopes in accordance with the invention. The antigen presenting
cell can be a "professional" antigen presenting cell, such as a
dendritic cell. The antigen presenting cell can comprise the
epitope of the invention by any means known or to be determined in
the art. Such means include pulsing of dendritic cells with one or
more individual epitopes or with one or more peptides that comprise
multiple epitopes, by nucleic acid administration such as ballistic
nucleic acid delivery or by other techniques in the art for
administration of nucleic acids, including vector-based, e.g. viral
vector, delivery of nucleic acids.
[0215] Further embodiments of compositions in accordance with the
invention comprise nucleic acids that encode one or more peptides
of the invention, or nucleic acids which encode a polyepitopic
peptide in accordance with the invention. As appreciated by one of
ordinary skill in the art, various nucleic acids compositions will
encode the same peptide due to the redundancy of the genetic code.
Each of these nucleic acid compositions falls within the scope of
the present invention. This embodiment of the invention comprises
DNA or RNA, and in certain embodiments a combination of DNA and
RNA. It is to be appreciated that any composition comprising
nucleic acids that will encode a peptide in accordance with the
invention or any other peptide based composition in accordance with
the invention, falls within the scope of this invention.
EXAMPLES
Preparation A
Peptide Synthesis and Generation of Peptide Analogs
[0216] The peptides used in these examples are shown in Table 1.
All of the wildtype human CTL epitopes derived from
tumor-associated antigens, as well as the wildtype viral epitopes
derived from the polymerase genes of the HIV and hepatitis B virus
(HBV.sup.2), have shown immunogenicity in human and transgenic
mouse systems (Kawashima, I., et al., Human Immunol. (1998) 59:1;
Ishioka, G., et al., J. Immunol. (1999) 162:3915; Epimmune,
unpublished data).
[0217] Peptides that were tested initially for heteroclitic
activity were synthesized by Chiron Technologies (Victor,
Australia). Peptides requiring further biological characterization
were synthesized at Epimmune using conventional methods (Ruppert,
J., et al., Cell (1993) 74:929) and their purity was routinely
>95%, as determined by analytical reverse-phase HPLC. The
identity of the latter peptides was confirmed by mass spectral
analysis.
Preparation B
Scheme for Selection of Single Amino Acid Substitutions
[0218] Table 2 shows the similarity assignments between any given
amino acid pair so that a given amino acid substitution could be
characterized as being a conservative, semi-conservative, or
non-conservative substitution.
[0219] The degree of similarity between amino acid pairs was
quantified by averaging, for each amino acid pair, the rank
coefficient scores for PAM250, hydrophobicity, and side chain
volume as described below. Based on the average values of these
composite rankings, the table shows each pair to be conserved,
semi-conserved or non-conserved.
[0220] The Dayhoff PAM250 score (Dayhoff, M. O., et al., Atlas of
Protein Sequence and Structure, Vol. 5, suppl. 3. (1978) M. O.
Dayhoff, ed. National Biomedical Research Foundation, Washington
D.C., p. 345; Creighton, T. E., Proteins: structures and molecular
properties (1993) (2nd edition) W.H. Freeman and Company, NY;
http://prowl.rockefeller.edu/aainfo/pam250. html) is a commonly
utilized protein alignment scoring matrix which measures the
percentage of acceptable point mutations (PAM) within a defined
time frame. The frequencies of these mutations are different from
what would be expected from the probability of random mutations,
and presumably reflect a bias due to the degree of physical and
chemical similarity of the amino acid pair involved in the
substitution. To obtain a score of amino acid similarity that could
be standardized with other measures of similarity, the PAM250
scores were converted to a rank value, where I indicates the
highest probability of being an accepted mutation.
[0221] The most commonly utilized scales to represent the relative
hydrophobicity of the 20 naturally occurring amino acids (Cornette,
J., et al, J. Mol. Biol. (1987) 195:659) are those developed on the
basis of experimental data by Kyte and Doolittle (Kyte, J. and R.
F. Doolittle, J. Mol. Biol. (1982) 157:105), and by Fauchere and
Pliska (Fauchere, J. and V. Pliska, Eur. J. Med. Chem. (1983)
18:369). The Kyte/Doolittle scale measures the H.sub.2O/organic
solvent partition of individual amino acids. Because it considers
the position of amino acids in folded proteins, it may most
accurately reflect native hydrophobicity in the context of
proteins. The Fauchere/Pliska scale measures the octanol/H.sub.2O
partitioning of N-acetyl amino acid amides, and most accurately
reflects hydrophobicity in the context of denatured proteins and/or
small synthetic peptides. To obtain scores for hydrophobicity, each
amino acid residue was ranked on both the Kyte/Doolittle and
Fauchere/Pliska hydrophobicity scales. An average rank between the
two scales was calculated and the average difference in
hydrophobicity for each pair was calculated.
[0222] Finally, for calculating amino acid side-chain volume, the
partial volume in solution obtained by noting the increase in
volume of water after adding either one molecule or one gram of
amino acid residue was considered (Zamyatnin, A. A., Ann. Rev.
Biophys. Bioeng. (1984) 13:145; Zamyatnin, A. A., Prog. Biophys.
Mol. Biol. (1972) 24:107). The absolute difference in the partial
volume of each possible pairing of the 20 naturally occurring amino
acids was calculated and ranked, where I indicated residues with
the most similar volumes, and 20 the most dissimilar.
Preparation C
Materials for Assays
[0223] 1. APC Lines
[0224] Cell lines that present peptides in the context of HLA-A2.1
were prepared as follows:
[0225] The 0.221A2.1 cell line was generated by transfecting the
HLA-A2.1 gene into the HLA-A, -B, -C-null mutant EBV-transformed
human B-lymphoblastoid cell line 3A4-721.221 (Kawashima, I., et
al., Human Immunol. (1998) 59:1). The cell line GM3107 was used as
APCs to measure B7 CTL responses.
[0226] Tumor cell lines were prepared by transfection of Meth A
cells, a methylcholanthrene-induced sarcoma, and the Jurkat cell
line with the HLA-A2.1 or HLA-A2.1/K.sup.b transgene transfection
was performed using methods described elsewhere (Vitiello, A., et
al., J. Exp. Med. (1991) 173:1007). A combination of the HLA-typed
melanoma cell lines 624mel (A2.1.sup.+, MAGE.sup.+) and 888mel
(A2.1.sup.-, MAGE.sup.-), were kindly provided by Y. Kawakami and
S. Rosenberg (National Cancer Institute), and were used to measure
presentation of endogenously processed MAGE3 epitopes (Boon, T., et
al., Ann. Rev. Immunol. (1994) 12:337). The melanoma cell lines
were treated with 100 IU/ml human IFN.gamma. (Genzyme, Cambridge,
Mass.) for 48 h at 37.degree. C. before using as APC.
[0227] All cells in this study were grown in RPMI-1640 medium
supplemented with antibiotics, sodium pyruvate, nonessential amino
acids, and 10% (v/v) heat-inactivated FBS.
[0228] 2. In Vitro Induction of CTL from Human PBMC and Derivation
of Human CTL Lines
[0229] To generate peptide-specific CTL lines against the
MAGE3.112, MAGE2.170, and a carcinoembryonic antigen (CEA) epitope,
CEA.691, PBMC from normal subjects were stimulated repeatedly in
vitro with peptide as described (Kawashima, I., et al., Human
Immunol. (1998) 59:1). Briefly, peptide-pulsed dendritic cells
(differentiated from adherent PBMC by culturing in GM-CSF and IL4)
were co-cultured with autologous CD8.sup.+ T cells, obtained by
positive selection with antibody-coated beads (Dynal A. S., Oslo,
Norway or Miltenyi Biotec, Auburn, Calif.) in a 48-well plate.
After 7 days of culture in the presence of IL2, IL7, and IL10, each
PBMC culture (well) was restimulated in vitro with adherent PBMC
pulsed with peptide. Cultures were then tested for CTL activity by
measuring IFN.gamma. production after stimulation with 0.221A2.1
tumor APC (A2 epitopes) or GM3107 tumor cells (B7 epitopes), in the
presence or absence of peptide. CTL lines were expanded from PBMC
cultures demonstrating peptide-specific IFN.gamma. responses by
additional in vitro stimulation with adherent peptide-pulsed
PBMC.
[0230] 3. Murine CTL Lines
[0231] CTL lines against epitopes HBV Pol.455 and HIV Pol.476
peptides were generated in HLA-A2.1/K.sup.bxs transgenic mice by
DNA immunization as described elsewhere (Ishioka, G., et al., J.
Immunol. (1999) 162:3915). HLA-A2.1/K.sup.bxs and
HLA-A2.1/K.sup.bxd transgenic mice were bred at Epimmune. These
strains represent the F1 generation of a cross between an
HLA-A2.1/K.sup.b transgenic strain generated on the C57BL/6
background (Vitiello, A., et al., J. Exp. Med. (1991) 173:1007),
and SJL or BALB/c mice (Jackson Laboratories, Bar Harbor, Me.),
respectively. A CTL line against the MAGE2.157 epitope was
generated by immunizing 8-12 wk old HLA-A2.1/K.sup.bxs mice s.c. at
the tail base with 50 .mu.g of peptide and 140 .mu.g of the HBV
Core.128 Th epitope, TPPAYRPPNAPIL (SEQ ID NO:30), emulsified in
IFA and restimulating primed splenocytes repeatedly in vitro with
peptide.
Preparation D
Assay Methods
[0232] 1. Measurement of Peptide Binding Affinity for HLA-A2.1 or
HLA-B7 Molecules
[0233] Binding of test peptides to HLA-A2.1 was measured by
determining the level of competition induced by a given test
peptide for binding of a radiolabeled standard peptide to HLA-A2.1.
The percentage of MHC-bound radioactivity was determined by gel
filtration and the concentration of test peptide that inhibited 50%
of the binding of the labeled standard peptide (IC.sub.50) was
calculated (Ruppert, J., et al, Cell (1993) 74:929; Sette, A., et
al, Mol. Immunol. (1994) 31:813). The standard peptide was the HBV
Core. 18 epitope (sequence FLPSDFFPSV) (SEQ ID NO:31). A similar
assay was performed to determine the binding affinity of peptides
to purified HLA-B7 (B*0702) molecules. In the latter assay, the
radiolabeled standard peptide was the SS 5-13a (L.sub.7.fwdarw.Y)
peptide (sequence APRTLVYLL) (SEQ ID NO:39).
[0234] 2. Measurement of Murine and Human IFN.gamma., IL5, and IL10
Production by CTL
[0235] An in situ capture ELISA was used for measuring IFN.gamma.
release from CTL (McKinney, D., et al., J. Immunol. Methods (2000)
237:105). Briefly, CTL were stimulated with APC and peptide in
ELISA-grade 96-well flat bottom wells that were precoated with
either an anti-mouse IFN.gamma. (clone R4-6A2, Pharmingen, San
Diego, Calif.) or anti-human IFN.gamma. mAb (clone NIB42,
Pharmingen). After culturing cells, wells are washed and developed
by adding a biotinylated anti-mouse IFN.gamma. (clone XMG1.2,
Pharmingen) or anti-human IFN.gamma. (clone 4S.B3, Pharmingen) mAb
followed by enzyme-conjugated streptavidin (Zymed, South San
Francisco, Calif.) and 3, 3', 5, 5' tetramethylbenzidine substrate
(ImmunoPure TMB substrate kit, Pierce, Rockford, Ill.). The
absorbance of each well was measured at 450 nM on a Labsystems
Multiskan RC ELISA plate reader. The level of IFN.gamma. produced
in each well was determined by extrapolation from a mouse or human
IFN.gamma. standard curve established in the same assay.
[0236] Murine and human IL5 and IL10 were measured in culture
supernates using ELISA kits (R&D Biosystems, Minneapolis,
Minn.). These assays, employing the quantitative sandwich ELISA
technique, were performed according to the manufacturer's
protocol.
[0237] 3. Enzyme-Liked Immunospot (Elispot) Assay for Measuring Ex
Vivo CTL Responses
[0238] Elispot assays were performed according to standard
protocols (Murali-Krishna, K., et al., Immunity (1998) 8:177;
Lewis, J. J., et al., Int. J. Cancer (2000) 87:391). Briefly, flat
bottom 96-well nitrocellulose plates (Immobilon-P membrane,
Millipore, Bedford, Mass.) were coated with anti-IFN.gamma. mAb (10
.mu.g/ml, clone R4-6A2) and incubated overnight at 4.degree. C.
After washing with PBS, plates were blocked with RPMI medium
containing 10% FBS for 1 h at 37.degree. C. Four.times.10.sup.5
splenic CD8.sup.+ cells isolated by magnetic beads (Miltenyi,
Auburn, Calif.) and 5.times.10.sup.4 Jurkat-A2.1/K.sup.b cells
pulsed with 10 .mu.g/ml of peptide were added to each well and
cells were incubated for 20 h in RPMI medium containing 10% FBS.
After incubation, the plates were washed thoroughly with PBS/0.05%
Tween and biotinylated anti-IFN.gamma. mAb (2 .mu.g/ml, clone
XMG1.2) was added to each well and plates were incubated for 4 h at
37.degree. C. Plates were then washed four times with PBS
(containing 0.1% Tween-20) and Vectastain ABC peroxidase
(Vectastain Elite kit; Vector Laboratories, Burlingame, Calif.).
After incubating for 1 h at room temperature, plates were washed
three times with 1.times.PBS/0.05% Tween followed by three
additional washes with 1.times.PBS. One hundred .mu.l of AEC
solution (Sigma Chemical, St. Louis, Mo.) was added to develop the
spots. The reaction was stopped after 4-6 min under running tap
water. The spots were counted by computer-assisted image analysis
(Zeiss KS Elispot Reader, Jena, Germany). The net number of
spots/10.sup.6 CD8.sup.+ cells was calculated as follows: [(number
of spots against relevant peptide)-(number of spots against
irrelevant control peptide)].times.2.5.
Example I
Screening of Peptide Analogs for Heteroclitic Activity
[0239] A. Identification of CEA.691 and MAGE3.112 Analogs
Associated with Increased IFN.gamma. Release
[0240] Prior to screening analogs, a peptide dose titration of
IFN.gamma. production from CTL lines was performed over a wide
range of doses of wildtype peptide. 0.221A2.1 tumor cells were
pulsed with varying doses of peptide then 10.sup.5 peptide-loaded
cells were cultured with an equivalent number of murine or human
CTL. After 24 hr (murine) or 48 hr (human) incubation at 37.degree.
C., levels of IFN.gamma. released by CTL were measured by the in
situ capture ELISA assay. After determining a dose titration curve,
a suboptimal peptide dose where activity against wildtype peptide
was barely detectable was selected for screening the antigenicity
of a panel of peptide analogs. For all of the murine and human CTL
lines, this suboptimal dose ranged from 0.1-1 .mu.g/ml. It should
be noted that although murine CTL lines were generated in
HLA-A2.1/K.sup.bxs transgenic mice which express an HLA molecule
with murine H-2 K.sup.b sequences in the third domain, all
responded to peptide presented on APC expressing the native
HLA-A2.1 molecule.
[0241] For screening of peptide analogs, 0.221A2.1 cells were
pulsed with each analog at the selected suboptimal dose and
peptide-loaded APC were cultured with CTL as described above.
Analogs inducing enhanced CTL responses relative to wildtype
peptide were then selected for further characterization. These
analogs were characterized by performing a peptide dose titration
side-by-side with the wildtype epitope under identical conditions
described above.
[0242] CTL lines specific for the HLA-A2.1-restricted CEA.691 and
MAGE3.112 epitopes were derived by repeated in vitro restimulations
of human PBMCs with peptide-loaded dendritic cells or adherent
monocytes, as described in Preparation C.
[0243] A total of 117 CEA.691 and 116 MAGE3.112 analogs were
generated by systematically replacing each residue with 17
different single amino acids. CEA.691 is IMIGVLVGV (SEQ ID NO: 1);
MAGE3.112 is KVAELVHFL (SEQ. ID. NO: 4). The residues Cys, Trp and
Met were in general avoided unless they corresponded to
conservative changes. Substitutions were introduced at all
positions in the peptide except at the main MHC anchor positions,
position 2 and the C-terminus.
[0244] These analogs were then tested in vitro for their
antigenicity. As described above, preliminary dose titration
experiments for each CTL line were performed to define an antigen
concentration at which IFN.gamma. production in response to
wildtype peptide was barely detectable. This suboptimal
concentration was then used subsequently for all antigenicity
analysis on analog peptides for each epitope, to identify analogs
associated with increased T cell stimulatory capacity. Results of
such antigenicity analysis are shown in FIG. 1. As shown in FIG.
1A, the suboptimal 100 ng/ml dose the wildtype CEA.691 peptide
yielded only marginal IFN.gamma. production (<50 pg/well). By
contrast, at the same dose, several CEA.691 analogs (M3, L4, P4,
H5, L5, H6, T6, and 17) induced detectable levels of IFN.gamma.
production, in the 150 to 350 pg/well range. As shown in FIG. 1B,
MAGE3.112-specific CTL line 100 ng/ml of wildtype peptide induced
the release of 100 pg/ml of IFN.gamma., whereas two analogs (I5 and
W7) were associated with inducing IFN.gamma. levels of over 300
pg/well.
[0245] All analogs of CEA.691 and MAGE3.112 that stimulated
IFN.gamma. above 100 pg/well were chosen for further
characterization and a complete dose titration was carried out to
identify heteroclitic analogs. Heteroclitic analogs are those that
stimulate significant IFN.gamma. release (>100 pg/well) at
10-fold or lower peptide concentrations than wildtype peptide. For
the CEA.691 epitope two different analogs, M3 (SEQ ID NO: 2) and H5
(SEQ ID NO: 3), were identified. As seen in FIG. 1C, for epitope
CEA.691, the wildtype peptide yielded a significant detectable
IFN.gamma. signal in the 1 to 100 .mu.g/ml dose range, while the
analogs M3 and H5 stimulated significant release with as little as
0.01 ng/ml of peptide. By these criteria, these two CEA.691 analogs
are, on a molar basis, 100,000-fold more potent in terms of
IFN.gamma. release than their unmodified wildtype counterpart.
[0246] Similarly, for the MAGE3.112 epitope two heteroclitic
analogs, I5 and W7, were identified. As shown in FIG. 1D, 1
.mu.g/ml of wildtype peptide concentration is required for
significant IFN.gamma. release whereas 0.1 ng/ml of either I5 (SEQ
ID NO:5) or W7 (SEQ ID NO:6) analogs was required to stimulate an
equivalent response. This corresponds to a greater than
100,000-fold increase in biological activity compared to wildtype
peptide.
[0247] In general, the modification of a wildtype Class I epitope
by substitution with a conservative or semi-conservative amino acid
at position 3 and/or 5 and/or 7 of the epitope to generate a
heteroclitic analog enhances the immune response to the
corresponding wildtype epitope. The heteroclitic analogs not only
induced a dose response shift, but also stimulated CTL's to produce
higher levels of IFN.gamma. compared to wildtype peptide so that
the maximal dose response (plateau) reached in response to the
analog was much higher than the response obtained in response to
the unmodified antigen.
Example 2
Identification of Additional Heteroclitic Analogs
[0248] Three additional A2.1-restricted epitopes, the MAGE2.157
YLQLVFGIEV, SEQ ID NO: 7 tumor epitope, and two epitopes from viral
antigens, HBV Pol.455, GLSRYVARL (SEQ ID NO: 16) and HIV Pol.476
ILKEPVHGV (SEQ ID NO: 18), were analyzed. All of these epitopes
have previously been shown to be immunogenic for CTL.
[0249] A panel of 240 different analogs was synthesized which
included five conservative and five non-conservative amino acid
substitutions at epitope positions 3, 5, 7 in each of the three
epitopes, as well as at epitope positions 1, 4, 6, using the amino
acid conservancy assignments described in the Preparation B and in
Table 2. These analogs were tested for heteroclicity using murine
CTL lines generated in HLA-A2.1/K.sup.bxs transgenic mice and
following an experimental strategy similar to the one described in
Example 1 for the CEA.691 and MAGE3.112 epitopes. Murine CTL lines
derived from HLA transgenic mice were used instead of human CTL
lines due to technical ease associated with generating and
maintaining mouse lines.
[0250] The results are shown in FIG. 2A (MAGE2.157), 2B (HBV
Pol.455), and 2C (HIV Pol.476) with a corresponding dose titration
profile for HIV Pol.476 in FIG. 2D. (See Example 3 for MAGE2.157
and HIV Pol.455).
[0251] Analysis of a total of 85 different analogs of the MAGE2.157
epitope tested resulted in identification of two heteroclitic
analogs, I5 (SEQ ID NO: 8) and F5 (SEQ ID NO: 9), that stimulated
IFN.gamma. responses at 100- to 100,000-fold lower doses than
wildtype peptide (Table 1); both of these analogs had substitutions
that were conservative or semi-conservative in nature occurring at
an odd-numbered position in the center of the peptide (position
5).
[0252] For the HIV Pol.476 epitope, out of 78 different analogs
screened, two were identified as having heteroclitic activity (H3
(SEQ ID NO: 19) and L3 (SEQ ID NO: 20)) (Table 1); both analogs
carried either a conservative or semi-conservative substitution at
an odd-numbered position in the center of the peptide. one
heteroclitic analog of HIV Pol.455 epitope out of 77 tested was
identified; this analog had a conservative substitution (P) at
position 7 of the peptide (SEQ ID NO: 17) (Table 1). An additional
HIV Pol.476 analog is prepared and tested (ILIEPVHGV) (SEQ ID NO:
53).
[0253] Thus, data obtained from 240 analogs for three additional
epitopes of tumor and viral origin (MAGE2.157, HIV Pol.476, and HBV
Pol.455), were consistent with the analysis of the MAGE3.112 and
CEA.691 epitopes as set forth in Example 1.
[0254] Heteroclicity analysis was also performed on two p53
epitopes. One epitope, p53.149M2, SMPPPGTRV (SEQ ID NO: 10)
represents a fixed anchor analog of a human p53 epitope having a
methionine residue substitution which enhances MHC binding. The
second epitope, p53 Mu.184, GLAPPQHLIRV (SEQ ID NO: 13) has a
sequence that is completely conserved between mice and humans
(Theobald, et al., 92 (26): 11993 (1995)).
[0255] Dose titration analysis performed on the p53.149M2 revealed
optimal and suboptimal responses at 1 .mu.g/ml and 0.1 .mu.g/ml
dose range. A panel of 76 analogs for p53.149M2 (five conservative
and five non-conservative substitutions at each position) was
screened and only two analogs, C1 (SEQ ID NO: 11) and P7 (SEQ ID
NO: 12), were identified both giving IFN.gamma. release of 100
pg/well at a suboptimal dose, FIG. 5. On further analysis, both
analogs induced significant IFN.gamma. production at 10-fold lower
concentrations than wildtype peptide. In addition, the C1 analog
also induced significant IL10 levels at 100-fold lower peptide
concentrations, FIG. 6.
[0256] For the p53mu.184 epitope optimal and suboptimal levels of
peptide were determined to be 500 ng/ml and 10 ng/ml respectively
after performing a dose titration analysis. A panel of 63
conservative and semi-conservative substitution analogs were tested
for immunogenicity. Two analogs with enhanced immunogenicity were
found--T3 (SEQ ID NO: 14) and T3,E6 (SEQ ID NO: 15). See FIGS. 7
and 8.
Example 3
Lymphokine Profile Induced by Heteroclitic Analogs
[0257] Heteroclitic analogs have been shown previously to
differentially activate cytokine production from T cells whereby
some analogs specifically activate T cells to produce Th1 cytokines
whereas others preferentially activate the production of Th2
cytokines. To investigate the pattern of lymphokine release
associated with the heteroclitic analogs of the invention, the
production of Th2 cytokines IL5 and/or IL10 from CTL lines was
compared to the production of IFN.gamma.. Representative data from
two different epitopes are shown in FIGS. 3 and 4.
[0258] FIGS. 3A and 3B show the lymphokine profile induced by
MAGE2.157 analogs. IFN.gamma. (A) and IL10 (B) produced by
MAGE2.157-specific CTL's in response to 0.221A2.1 targets pulsed
with analogs I5 or F5, or wildtype (WT) peptide was measured over
several different doses. Dotted lines indicate significant levels
of IFN.gamma. (100 pg/well) or IL10 (50 pg/ml). As seen in FIG. 3A,
the F5 and I5 analogs of MAGE2.157 induced significant levels of
IFN.gamma. production at 100-fold or 10,000-fold lower
concentrations than wildtype peptide respectively. Moreover, the
same analogs also induced significant IL10 production at 10-fold or
100-fold lower peptide concentrations than wildtype peptide.
[0259] Data from another epitope, HBV Pol.455, depicting the same
trend are shown in FIGS. 4A and 4B. IFN.gamma. (A) or IL10 (B)
released by HBV Pol.455 CTL's in response to analog P7 or wildtype
(WT) peptide over several different peptide doses are shown. Once
again, the P7 analog of HBV Pol.455 induced significant levels of
IFN.gamma. (FIG. 4A) and IL10 (FIG. 4B) at 100-fold lower peptide
concentrations than wildtype peptide. Taken together the data
summarizing all the heteroclitic analogs tested for induction of
Th2 cytokines (Table 6) indicates that most heteroclitic analogs
stimulate increased production of both of Th1 and Th2
cytokines.
Example 4
HLA-A2.1 Binding Affinity of Heteroclitic Analogs
[0260] To verify that the enhanced recognition by CTL lines
observed was not due to a fortuitous increase in MHC binding
capacity of the analog epitope, the MHC binding affinity of all
heteroclitic analogs was measured in vitro utilizing purified
HLA-A2.1 molecules, and compared to their unmodified wildtype
counterparts as described in Preparation D.
[0261] As summarized in Table 6, three analogs (MAGE3.112 W7, HIV
Pol.476H3, and HIV Pol.476 L3) bound to HLA-A2.1 with four-fold or
higher affinity than wildtype peptide and two analogs bound with
lower affinity (MAGE2.157 I5, MAGE2.157 F5). The four remaining
heteroclitic analogs, MAGE3.112 I5, CEA.691 M3, CEA.691 H5, and HBV
Pol.455 P7, were associated with little or no change in HLA-A2.1
binding capacity. Collectively these data suggest a lack of
correlation between increased binding and heteroclicity.
Example 5
Prediction and Immunogenicity of Analogs for the Murine p53.261
Epitope
[0262] To test for immunogenicity in vivo, the HLA-A2.1-restricted
murine p53.261 epitope was used since CTL responses against this
epitope have been shown to be partially tolerized in
HLA-A2.1/K.sup.b transgenic mice. This permits analysis of the
capacity of predicted heteroclitic analogs to break T cell
tolerance in vivo. Although heteroclitic analogs heretofore have
been detected through in vitro screening with CTL lines raised
against wildtype epitopes, we reasoned that analogs identified by
the substitution rules could potentially induce CTL in vivo that
were heteroclitic against the wildtype epitope, an application of
interest for designing vaccines against tolerant tumor-associated
epitopes.
[0263] Immunogenicity for the p53.261 predicted analogs were tested
in HLA-A2.1/K.sup.bxd transgenic mice by co-immunizing mice with 50
.mu.g of the p53.261 epitope (LLGRDSFEV) (SEQ ID NO:21) or its
predicted analogs and 140 .mu.g of HBV Core. 128 helper epitope in
IFA. Eleven days later, primed spleen cells were harvested and
cultured in vitro with irradiated syngeneic LPS-activated spleen
cells that had been pulsed with 10 .mu.g/ml of peptide. After 10
days of culture, CTL were restimulated with peptide-pulsed LPS
blasts in the presence of Con A-conditioned media as a source of
IL2 (Ishioka, G., et al., J. Immunol. (1999) 162:3915). Spleen
cells from mice immunized with the predicted analogs were
stimulated in vitro against both wildtype peptide (to determine the
cross-reactivity, avidity and precursor frequency of CTL's that
respond to wildtype antigen) and the respective immunizing analog
(to determine avidity and precursor frequency of CTL's responding
to the analog). All short-term, bulk populations of CTL were tested
for peptide specificity by the IFN.gamma. in situ ELISA assay 5
days after the second restimulation in vitro, using Jurkat-A2.1
tumor cells as APC. Alternatively, CTL responses were performed on
freshly isolated spleen cells from immunized animals using the
Elispot assay.
[0264] A panel of nine analogs of the p53.261 epitope consisting of
three conservative or semi-conservative substitutions at positions
3, 5, and 7 of the 9-mer peptide was tested for immunogenicity in
HLA-A2.1/K.sup.bxd transgenic mice. Immunization of mice with each
of the nine analogs and in vitro expansion of primed splenocytes
with the respective immunizing analog resulted in identification of
six analogs (L7, D3, H7, H3, N5, G5) that gave CTL responses
characterized by IFN.gamma. production of 100 pg/well at much lower
peptide concentrations compared to CTL induced in vivo and expanded
in vitro with wildtype peptide.
[0265] Spleen cells from mice immunized with either WT peptide or
the indicated analogs were stimulated in vitro with the
corresponding immunizing peptide (FIGS. 9A, B) or with WT peptide
(FIGS. 9C, D). IFN.gamma. release by these CTL's was then measured
over a dose range against targets pulsed with the immunizing
peptide (FIGS. 9A, B) or with WT peptide (FIGS. 9C, D). IFN.gamma.
release at 100 pg/well is shown as a dotted line. These results
indicate that a significant percentage of the analogs induce CTL of
a higher avidity than those induced by wildtype peptide itself.
[0266] The cross-reactivity of CTL primed with these heteroclitic
analogs against wildtype peptide is shown in FIG. 9C and FIG. 9D.
While CTL's obtained from animals immunized and restimulated with
wildtype peptide induced 100 pg/well IFN.gamma. at peptide doses
between 0.1-110 .mu.g/ml, CTL's obtained from animals immunized
with analogs L7, H3, and D3, and stimulated and tested in vitro
with wildtype peptide, required 10-, 100-, or 1000-fold lower doses
of wildtype peptide respectively, to induce 100 pg/well of
IFN.gamma. (FIG. 9C). This suggests that in three out of six cases
the predicted heteroclitic analogs were 10-1000-fold more
active/potent at inducing CTL's reactive to wildtype peptide in
situations where partial CTL tolerance to wildtype antigen
exists.
Example 6
Cross Reactivity with Wildtype
[0267] The cross-reactivity of CTL induced by the D3 and H3 analogs
were also tested against the wildtype epitope naturally processed
by a p53-expressing Meth A tumor cell clone transfected with
HLA-A2.1/K.sup.b; it was found that CTL generated by p53.261
analogs that are heteroclitic for wildtype epitope respond to
endogenously-processed p53.261 epitope presented by Meth
A/A2.1K.sup.b tumor cells.
[0268] The CTL population (10.sup.5/well) were cultured with
2.5.times.10.sup.4 Meth A tumor cells or with a Meth A clone
transfected with HLA-A2.1/K.sup.b and IFN.gamma. release was
measured by the in situ ELISA assay. As shown in FIG. 10, CTL lines
raised against both D3 and H3 analogs of the p53.261 epitope
responded to the endogenous epitope expressed by a Meth
A/A2.1K.sup.b tumor cell clone but not to the parental
HLA-A2.1-negative Meth A tumor cell line.
Example 7
Precursor Frequency Analysis Using Elispot Assays
[0269] To confirm that cross-reactive CTL against wildtype peptide
are generated in mice immunized with analogs CD8.sup.+ cells were
isolated from spleen cells of mice immunized with analogs or
wildtype peptide, without further CTL expansion in vitro and the
precursor frequency of CTL reactive against either wildtype or
analog was determined using an Elispot assay.
[0270] CD8.sup.+ cells isolated from mice immunized with either WT
peptide or the D3, H3, L7, and H7 analogs were analyzed for their
ability to release IFN.gamma. when stimulated in the Elispot assay
with WT peptide. FIG. 11 shows that while the precursor frequencies
of wildtype peptide-reactive CTL were 1/66,000 (15 spots/10.sup.6)
in mice immunized with wildtype peptide, precursor frequencies of
wildtype peptide-reactive cells in mice immunized with predicted
analogs were approximately 1/15,000 for analogs D3, H3, and L7
(60-75 spots/10.sup.6 cells), and 1/83,000 (12 spots/10.sup.6) for
analog H7. This indicates wildtype-reactive cells were present at a
four-fold higher frequency in mice immunized with three out of the
four analogs compared to mice immunized with the native peptide.
This finding is significant since it implies that in vivo
immunization with heteroclitic analogs does indeed induce a higher
number of CTL reactive against wildtype peptide, using a more
direct assay system where in vitro expansion of in vivo-primed CTL
is avoided.
Example 8
Heteroclitic Analogs Induce Human CTL Capable of Recognizing Tumor
Cells In Vitro
[0271] Immunogenicity of heteroclitic analogs of MAGE3.112 was also
tested by inducing primary CTL from PBMC, as described in
Preparation C, against either the MAGE3.112 peptide or the I5 and
W7 analogs of this epitope. After two rounds of in vitro
stimulation, PBMC cultures in 48-wells were scored positive for CTL
induction if the net IFN.gamma. production was >100 pg/well and
production was at least two-fold above background, after
stimulating with 0.221-A2.1 APC in the presence or absence of
peptide.
[0272] To underline the physiologic relevance of our observations
to human tumor antigens, we examined whether heteroclitic analogs
of the MAGE3.112 epitope could induce human CTL's in a primary in
vitro induction system. Fresh naive human PBMC from normal donors
were stimulated repetitively in vitro with either wildtype or
analogs as described previously (Kawashima, I., et al., Human
Immunol. (1998) 59:1). Peptide-specific CTL responses were detected
in cultures stimulated with either wildtype peptide (FIG. 12A) or
the I5 (FIG. 12B) and W7 analogs (FIG. 12C). Briefly, 0.221A2.1
cells were pulsed overnight with 10 .mu.g/ml of WT peptide (FIG.
12A), the I5 (FIG. 12B) analog, or the W7 analog (FIG. 12C).
IFN.gamma. production by CTL's growing in individual wells from a
48-well plate were tested against 0.221A2.1 cells in the presence
or absence of peptide, or against the endogenous epitope-negative
888mel and the endogenous epitope-positive 624mel tumor cell lines.
Only wells showing a positive peptide-specific CTL response are
shown.
[0273] More importantly cultures induced with these analogs
recognized the 624mel tumor cell line that endogenously processes
and presents the wildtype sequence. This demonstrates that
heteroclitic analogs can induce physiologically relevant human
CTL's that recognize endogenously-generated wildtype peptide
presented by tumor cells and that the phenomenon is relevant in
both human and in transgenic mouse systems.
Example 9
Synthesis and Analysis of Heteroclitic Analogs Derived from the
HLA-A2.1 Supermotif on HLA A2 Superfamily Members
[0274] To further validate the heteroclitic substitution rules for
other HLA molecules within the A2 superfamily, the panel of nine
analogs of the p53.261 epitopes discussed above consisting of three
conservative/semiconservative substitutions at positions 3, 5 and 7
are tested for in vivo immunogenicity in transgenic mice expressing
one of the following human HLA molecules: A*0202, A*0203, A*0204,
A*0205, A*0206, A*0207, A*0209, A*0214, A*6802 and A*6901.
[0275] CTLs from the mice immunized with the above-described
analogs are tested for induction of at least 100 pg/well of
IFN.gamma. production. This IFN.gamma. production typically occurs
at much lower peptide concentrations than those induced and
restimulated with wildtype peptide (e.g., the p53.261 epitope).
These results indicate that our predicted heteroclitic analogs are
more potent at inducing higher avidity CTL against the native
wildtype epitope than wildtype peptide itself.
[0276] Typically, CTLs obtained from animals immunized and
restimulated with a wildtype peptide will induce 100 pg/well
IFN.gamma. at peptide doses of 5-10 .mu.g/ml, whereas CTLs obtained
from animals immunized with the above-described analogs, and
stimulated and tested in vitro with wildtype peptide, require
10-fold, 100-fold or even 1000-fold lower doses of wildtype peptide
respectively, to induce 100 pg/well of IFN.gamma..
Example 10
Identification of Heteroclitic Analogs of a B7 Superfamily CTL
Epitope, MAGE2.170
[0277] To better define the application of the invention to HLA
Supertype families other than HLA-A2, analogs of the B7 superfamily
epitope MAGE2.170 (sequence VPISHLYIL) (SEQ ID NO:46) were
synthesized and screened in a fashion similar to that described
previously for A2 superfamily epitopes. A panel of analogs of the
MAGE2.170 epitope consisting of conservative/semi-conservative and
non-conservative substitutions at every non-anchor position were
screened at two suboptimal peptide doses using a human CTL line
generated against the wildtype epitope. As previously described,
this screening assay served to identify any potentially
heteroclitic analogs that induce stronger CTL responses compared to
wildtype peptide.
[0278] As shown in FIG. 13, analogs substituted at position 7 with
either a H, M, E, G, or D residue stimulated IFN.gamma. responses
that were greater than the wildtype peptide when tested at the 0.01
.mu.g/ml dose. When the stimulatory capacity of these five analogs
were further analyzed in a peptide dose titration using the same
wildtype epitope-specific CTL line, all of them demonstrated strong
heteroclitic activity inasmuch as they all stimulated an equivalent
level of IFN.gamma. production (e.g. 200 pg/well) at >10-fold
lower doses compared to the wildtype epitope, and the magnitude of
response stimulated by the analogs was >2-fold greater than
wildtype epitope at several peptide doses (FIG. 14).
[0279] To determine whether the heteroclitic activity of MAGE2.170
analogs was correlated with an increase or decrease in MHC binding
activity, the binding affinity of the H7, M7, E7, G7, and D7
analogs to purified HLA-B7 molecules was determined relative to the
wildtype epitope. Results shown in Table 7 indicate that there was
no correlation between MHC binding of the analogs and heteroclicity
inasmuch as 4 of the 5 MAGE2.170 analogs demonstrated binding
affinities within a two-fold range of the wildtype peptide. The
fifth epitope, MAGE2.170 D7, demonstrated a >100-fold decrease
in binding compared to the wildtype peptide, therefore an
enhancement in MHC binding could not account for the heteroclitic
activity observed with this analog.
[0280] In summary, these results indicate that heteroclitic analogs
can be generated from a B7 superfamily epitope by introducing
single amino acid substitutions and that the substitution pattern
showed similarity and differences with A2 heteroclitic epitopes.
Like A2 heteroclitic epitopes, heteroclitic analogs of the B7
superfamily epitope MAGE2.170 could be generated by introducing
substitutions at an odd-number position in the middle of the
peptide (position 7). The nature of the substitutions for the
MAGE2.170 epitope was either conservative/semi-conservative (the
Y.fwdarw.H and Y.fwdarw.M substitutions) or non-conservative (the
Y.fwdarw.E, Y.fwdarw.G, and Y.fwdarw.D substitutions) compared to
the native residue (Table 7). Thus, the observation that
non-conservative substitutions can result in heteroclitic analogs
for the MAGE2.170 CTL epitope indicate a partially overlapping
substitution pattern than that observed with A2 superfamily
epitopes.
Example 11
Synthesis and Analysis of Heteroclitic Analogs Derived from the
HLA-B7 Supermotif on HLA B7 Superfamily Members
[0281] To further validate the heteroclitic substitution rules,
additional studies are carried out with heteroclitic analogs
derived from a peptide bearing a sequence within the HLA-B7
supermotif. For example, the analogs can be tested for in vivo
immunogenicity.
[0282] For this study, the HLA-B7 supermotif bearing peptide,
APRTLVYLL (SEQ. ID. NO:39) epitope is chosen and synthesized. A
panel of analogs consisting of three conservative/semiconservative
substitutions at positions 3, 5 and 7 of the 9-mer peptide, are
tested for immunogenicity in HLA-B*0702/K.sup.b transgenic mice.
The panel includes APETLVYLL (SEQ ID NO:40), APRTWVYLL (SEQ ID
NO:41), and APRTLVPLL (SEQ ID NO:42), corresponding to a
semi-conservative change is the third, fifth and seventh position,
respectively.
[0283] CTLs from the mice immunized with the above-described
analogs are tested for induction of at least 100 pg/well of
IFN.gamma. production. This IFN.gamma. production will typically
occur at much lower peptide concentrations than those induced and
restimulated with wildtype peptide (e.g., APRTLVYLL) (SEQ ID
NO:39). These results will indicate that our predicted heteroclitic
analogs are more potent at inducing higher avidity CTL than
wildtype peptide itself.
[0284] Typically, CTLs obtained from animals immunized and
restimulated with a wildtype peptide will induce 100 pg/well
IFN.gamma. at peptide doses of 5-10 .mu.g/ml, whereas CTLs obtained
from animals immunized with the above-described analogs, and
stimulated and tested in vitro with wildtype peptide, require
10-fold, 100-fold or even 1000-fold lower doses of wildtype peptide
respectively, to induce 100 pg/well of IFN.gamma..
[0285] To further validate the heteroclitic substitution rules for
other HLA molecules with the B7 superfamily, the peptides APETLVYLL
(SEQ ID NO:40), APRTWVYLL (SEQ ID NO:41) and APRTLVPLL (SEQ ID
NO:42) are tested for in vivo immunogenicity in transgenic mice
expressing one of the following human HLA molecules: B*0702,
B*0703, B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B*3503,
B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103,
B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602,
B*6701 and B*7801.
[0286] CTLs from the mice immunized with the above-described
analogs are tested for induction of at least 100 pg/well of
IFN.gamma. production. This IFN.gamma. production will typically
occur at much lower peptide concentrations than those induced and
restimulated with wildtype peptide (e.g., APRTLVYLL) (SEQ ID
NO:39). These results will indicate that our predicted heteroclitic
analogs are more potent at inducing higher avidity CTL than
wildtype peptide itself.
[0287] Typically, CTLs obtained from animals immunized and
restimulated with a wildtype peptide will induce 100 pg/well
IFN.gamma. at peptide doses of 5-10 .mu.g/ml, whereas CTLs obtained
from animals immunized with the above-described analogs, and
stimulated and tested in vitro with wildtype peptide, require
10-fold, 100-fold or even 1000-fold lower doses of wildtype peptide
respectively, to induce 100 pg/well of IFN.gamma..
Precursor Frequency Analysis Using Elispot Assays
[0288] To confirm that cross-reactive CTL against wildtype peptide
are generated in mice immunized with analogs, CD8.sup.+ cells are
isolated from spleens immunized with analogs or wildtype peptide
without further CTL expansion in vitro. From this material, the
precursor frequency of CTL reactive against either wildtype or
analog using Elispot assay is determined. The precursor frequencies
of wildtype peptide reactive CTLs are typically much lower than the
precurser frequencies of the analogs.
Heteroclitic Analogs can Induce Human CTL Capable of Recognizing
Epitopes In Vitro
[0289] Heteroclitic analogs can be analyzed for induction of CTLs
in a primary in vitro induction system. Fresh naive human PBMC from
normal donors are stimulated repetitively in vitro, with either
wildtype or analogs, in 48 well plates as described previously.
Peptide specific CTL responses are then detected in cultures
stimulated with either a wildtype peptide or a heteroclitic analog.
Cultures induced with these analogs can recognize targets that are
endogenously processed and present the wildtype sequence. This
demonstrates that heteroclitic analogs can induce physiologically
relevant human CTLs that recognize endogenously generated wildtype
peptide expressed on cells and that the phenomenon is relevant in
both human and in transgenic mouse systems.
Example 12
Synthesis and Analysis of Heteroclitic Analogs Derived from the
HLA-A3 Supermotif on HLA A3 Superfamily Members
[0290] To further validate the heteroclitic substitution rules,
additional studies are carried out with heteroclitic analogs
derived from a peptide bearing a sequence within the HLA-A3
supermotif. For example, the analogs can be tested for in vivo
immunogenicity.
[0291] For this study, the HLA-A3 supermotif bearing peptide,
KVFPYALINK (SEQ ID NO:29) epitope is chosen and synthesized. A
panel of analogs of SEQ ID NO:29 consisting of three
conservative/semiconservative substitutions at positions 3, 5 and 7
of the 9-mer peptide, are tested for immunogenicity in
HLA-A*3101/K.sup.b transgenic mice. The panel includes KVHPYALINK
(SEQ ID NO:43), KVFPQALINK (SEQ. ID. NO:44) and KVFPYAKINK (SEQ ID
NO:45), corresponding to a semi-conservative change in the third,
fifth and seventh position, respectively.
[0292] CTLs from the mice immunized with the above-described
analogs are tested for induction of at least 100 pg/well of
IFN.gamma. production. This IFN.gamma. production typically occurs
at much lower peptide concentrations than those induced and
restimulated with wildtype peptide (e.g., KVFPYALINK) (SEQ ID
NO:29). These results indicate that our predicted heteroclitic
analogs are more potent at inducing higher avidity CTL against
wildtype than wildtype peptide itself.
[0293] Typically, CTLs obtained from animals immunized and
restimulated with a wildtype peptide induce 100 pg/well IFN.gamma.
at peptide doses of 5-10 .mu.g/ml, whereas CTLs obtained from
animals immunized with the above-described analogs, and stimulated
and tested in vitro with wildtype peptide, require 10-fold,
100-fold or even 1000-fold lower doses of wildtype peptide
respectively, to induce 100 pg/well of IFN.gamma..
[0294] To further validate the heteroclitic substitution rules for
other HLA molecules with the A3 superfamily, the peptides
KVHPYALINK (SEQ ID NO:43), KVFPQALI NK (SEQ ID NO:44) and
KVFPYAKINK (SEQ ID NO:45) are tested for in vivo immunogenicity in
transgenic mice expressing one of the following human HLA
molecules: A*0301, A*1101, A*3101, A*3301 and A*6801.
[0295] CTLs from the mice immunized with the above-described
analogs are tested for induction of at least 100 pg/well of
IFN.gamma. production. This IFN.gamma. production typically occurs
at much lower peptide concentrations than those induced and
restimulated with wildtype peptide (e.g., KVFPYALINK) (SEQ ID
NO:29). These results will indicate that our predicted heteroclitic
analogs are more potent at inducing higher avidity CTL than
wildtype peptide itself.
[0296] Typically, CTLs obtained from animals immunized and
restimulated with a wildtype peptide induce 100 pg/well IFN.gamma.
at peptide doses of 5-10 .mu.g/ml, whereas CTLs obtained from
animals immunized with the above-described analogs, and stimulated
and tested in vitro with wildtype peptide, require 10-fold,
100-fold or even 1000-fold lower doses of wildtype peptide
respectively, to induce 100 pg/well of IFN.gamma..
Precursor Frequency Analysis Using Elispot Assays
[0297] To confirm that cross-reactive CTL against wildtype peptide
are generated in mice immunized with analogs, CD8.sup.+ cells are
isolated from spleens immunized with analogs or wildtype peptide
without further CTL expansion in vitro. From this material, the
precursor frequency of CTL reactive against either wildtype or
analog using Elispot assay is determined. The precursor frequencies
of wildtype peptide reactive CTLs are typically much lower than the
precurser frequencies of the analogs.
Heteroclitic Analogs can Induce Human CTL Capable of Recognizing
Epitopes In Vitro
[0298] Heteroclitic analogs are analyzed for induction of CTLs in a
primary in vitro induction system. Fresh naive human PBMC from
normal donors are stimulated repetitively in vitro, with either
wildtype or analogs, in 48 well plates as described previously.
Peptide specific CTL responses are then detected in cultures
stimulated with either a wildtype peptide or a heteroclitic analog.
Cultures induced with these analogs recognize targets that are
endogenously processed and present the wildtype sequence. This
demonstrates that heteroclitic analogs induce physiologically
relevant human CTLs that recognize endogenously generated wildtype
peptide expressed on cells and that the phenomenon is relevant in
both human and in transgenic mouse systems.
[0299] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the spirit
and purview of this application and scope of the appended claims.
All publications, patents, and patent applications cited herein are
hereby incorporated by reference in their entirety for all
purposes.
TABLE-US-00001 TABLE 1 SEQ. ID NO:1 IMIGVLVGV CEA.691 SEQ. ID NO:2
IMMGVLVGV CEA.691 M3 SEQ. ID NO:3 IMIGHLVGV CEA.691 H5 SEQ ID NO:4
KVAELVHFL MAGE3.112 SEQ. ID NO:5 KVAEIVHFL MAGE3.112 I5 SEQ. ID
NO:6 KVAELVWFL MAGE3.112 W7 SEQ. ID NO:7 YLQLVFGIEV MAGE2.157 SEQ.
ID NO:8 YLQLIFGIEV MAGE2.157 I5 SEQ. ID NO:9 YLQLFFGIEV MAGE2.157
F5 SEQ. ID NO:10 SMPPPGTRV p53.149M2 SEQ. ID NO:11 CMPPPGTRV
p53.149M2 C1 SEQ. ID NO:12 SMPPPGPRV p53.149M2 P7 SEQ. ID NO:13
GLAPPQHLIRV p53.Mu.184 SEQ. ID NO:14 GLTPPQHLIRV p53.Mu.184 T3 SEQ.
ID NO:15 GLTPPEHLIRV p53.Mu.184 T3, E6 SEQ. ID NO:16 GLSRYVARL HBV
Po1.455 SEQ. ID NO:17 GLSRYVPRL HBV Po1.455 P7 SEQ. ID NO:18
ILKEPVHGV HIV Po1.476 SEQ. ID NO:19 ILHEPVHGV HIV Po1.476 H3 SEQ.
ID NO:20 ILLEPVHGV HIV Po1.476 L3 SEQ. ID NO:21 LLGRDSFEV p53.261
SEQ. ID NO:22 LLDRDSFEV p53.261 D3 SEQ. ID NO:23 LLHRDSFEV p53.261
H3 SEQ. ID NO:24 LLGRDSLEV p53.261 L7 SEQ. ID NO:25 LLGRDSHEV
p53.261 H7 SEQ. ID NO:26 LLGRNSFEV p53.261 N5 SEQ. ID NO:27
LLGRGSFEV p53.261 G5 SEQ. ID NO:28 APAAAAAAY SEQ. ID NO:29
KVFPYALINK A3 wildtype SEQ. ID NO:30 TPPAYRPPNAPIL HBVCore.128 Th
SEQ. ID NO:31 FLPSDFFPSV HBVCore.18 SEQ. ID NO:39 APRTLVYLL HLA-B7
SEQ. ID NO:48 VPISHLYIL MAGE2.170 SEQ. ID NO:49 VPISHLHIL MAGE2.170
H7 SEQ. ID NO:50 VPISHLMIL MAGE2.170 M7 SEQ. ID NO:51 VPISHLGIL
MAGE2.170 G7 SEQ. ID NO:52 VPISHLEIL MAGE2.170 E7 SEQ. ID NO:53
VPISHLDIL MAGE2.170 D7
TABLE-US-00002 TABLE 2 Compiled rankings and similarity
assignments. ##STR00001## ##STR00002## ##STR00003##
TABLE-US-00003 TABLE 3 POSITION POSITION POSITION 2 (Primary 3
(Primary C Terminus (Primary Anchor) Anchor) Anchor) SUPER- MOTIFS
A1 T, I, L, V, M, S F, W, Y A2 L, I, V, M, A, T, I, V, M, A, T, L Q
A3 V, S, M, A, T, L, R, K I A24 Y, F, W, I, V, L, F, I, Y, W, L, M
M, T B7 P V, I, L, F, M, W, Y, A B27 R, H, K F, Y, L, W, M, I, V, A
B44 E, D F, W, L, I, M, V, A B58 A, T, S F, W, Y, L, I, V, M, A B62
Q, L, I, V, M, P F, W, Y, M, I, V, L, A MOTIFS A1 T, S, M Y A1 D,
E, A, S Y A2.1 L, M, V, Q, I, A, V, L, I, M, A, T T A3 L, M, V, I,
S, A, K, Y, R, H, F, A T, F, C, G, D A11 V, T, M, L, I, S, K, R, Y,
H A, G, N, C, D, F A24 Y, F, W, M F, L, I, W A*3101 M, V, T, A, L,
I, R, K S A*3301 M, V, A, L, F, I, R, K S, T A*6801 A, V, T, M, S,
L, R, K I B*0702 P L, M, F, W, Y, A, I, V B*3501 P L, M, F, W, Y,
I, V, A B51 P L, I, V, F, W, Y, A, M B*5301 P I, M, F, W, Y, A, L,
V B*5401 P A, T, I, V, L, M, F, W, Y
Bolded residues are preferred, italicized residues are less
preferred: A peptide is considered motif-bearing if it has primary
anchors at each primary anchor position for a motif or supermotif
as specified in the above table.
TABLE-US-00004 TABLE 4 POSITION POSITION POSITION 2 (Primary 3
(Primary C Terminus (Primary Anchor) Anchor) Anchor) SUPER- MOTIFS
A1 T, I, L, V, M, S F, W, Y A2 V, Q, A, T I, V, L, M, A, T A3 V, S,
M, A, T, L, R, K I A24 Y, F, W, I, V, L, F, I, Y, W, L, M M, T B7 P
V, I, L, F, M, W, Y, A B27 R, H, K F, Y, L, W, M, I, V, A B58 A, T,
S F, W, Y, L, I, V, M, A B62 Q, L, I, V, M, P F, W, Y, M, I, V, L,
A MOTIFS A1 T, S, M Y A1 D, E, A, S Y A2.1 V, Q, A, T* V, L, I, M,
A, T A3.2 L, M, V, I, S, A, K, Y, R, H, F, A T, F, C, G, D A11 V,
T, M, L, I, S, K, R, H, Y A, G, N, C, D, F A24 Y, F, W F, L, I, W
*If 2 is V, or Q, the C-term is not L
[0300] Bolded residues are preferred, italicized residues are less
preferred: A peptide is considered motif-bearing if it has primary
anchors at each primary anchor position for a motif or supermotif
as specified in the above table.
TABLE-US-00005 TABLE 5 Allelle-specific HLA-supertype members
HLA-supertype Verified.sup.a Predicted.sup.b A1 A*0101, A*2501,
A*2601, A*2602, A*3201 A*0102, A*2604, A*3601, A*4301, A*8001 A2
A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0208,
A*0210, A*0211, A*0212, A*0213 A*0209, A*0214, A*6802, A*6901 A3
A*0301, A*1101, A*3101, A*3301, A*6801 A*0302, A*1102, A*2603,
A*3302, A*3303, A*3401, A*3402, A*6601, A*6602, A*7401 A24 A*2301,
A*2402, A*3001 A*2403, A*2404, A*3002, A*3003 B7 B*0702, B*0703,
B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B*1511, B*4201,
B*5901 B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101,
B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502,
B*5601, B*5602, B*6701, B*7801 B27 B*1401, B*1402, B*1509, B*2702,
B*2703, B*2704, B*2705, B*2706, B*2701, B*2707, B*2708, B*3802,
B*3903, B*3904, B*3801, B*3901, B*3902, B*7301 B*3905, B*4801,
B*4802, B*1510, B*1518, B*1503 B44 B*1801, B*1802, B*3701, B*4402,
B*4403, B*4404, B*4001, B*4002, B*4101, B*4501, B*4701, B*4901,
B*5001 B*4006 B58 B*5701, B*5702, B*5801, B*5802, B*1516, B*1517
B62 B*1501, B*1502, B*1513, B*5201 B*1301, B*1302, B*1504, B*1505,
B*1506, B*1507, B*1515, B*1520, B*1521, B*1512, B*1514, B*1510
.sup.aVerified alleles include alleles whose specificity has been
determined by pool sequencing analysis, peptide binding assays, or
by analysis of the sequences of CTL epitopes. .sup.bPredicted
alleles are alleles whose specificity is predicted on the basis of
B and F pocket structure to overlap with the supertype
specificity.
TABLE-US-00006 TABLE 6 Characterization of heterocyclic analogs
identified from tumor and viral antigens. SEQ Th1 Th2 A*0201 ID
Heterocyclic Type of Position of cyto- cyto- binding Antigen NO:
Sequence substitution substitution substitution kines.sup.a
kines.sup.b (IC50, nM).sup.d CEA.691 1 IMIGVLVGV None (WT) None 1
10 54 CEA.691 M3 2 IMMGVLVGV I.fwdarw.M Conservative 3 10.sup.-5 1
27 CEA.691 H5 3 IMIGHLVGV V.fwdarw.H Semi- 5 10.sup.-7 10.sup.-1 16
conservative MAGE3.112 4 KVAELVHFL None (WT) None 1 NS.sup.c 94
MAGE3.112 I5 5 KVAEIVHFL L.fwdarw.I Conservative 5 10.sup.-4 NS 66
MAGE3.112 W7 6 KVAELVWFL H.fwdarw.W Semi- 7 10.sup.-7 NS 7
conservative MAGE2.157 7 YLQLVFGIEV None (WT) None 1 10 40
MAGE2.157 I5 8 YLQLIFGIEV V.fwdarw.I Conservative 5 10.sup.-4
10.sup.-2 476 MAGE2.157 F5 9 YLQLFFGIEV V.fwdarw.F Semi- 5
10.sup.-2 10.sup.-2 212 conservative HBV Po1.455 16 GLSRYVARL None
(WT) None 10 10 83 HBV Po1.455 P7 17 GLSRYVPRL A.fwdarw.P
Conservative 7 10.sup.-2 10.sup.-2 267 HIV Po1.476 18 ILKEPVHGV
None (WT) >10 >10 369 HIV Po1.476 H3 19 ILHEPVHGV K.fwdarw.H
Conservative 3 1 1 78 HIV Po1.476 L3 20 ILLEPVHGV K.fwdarw.L Semi-
3 10.sup.-1 1 63 conservative .sup.aMinimum peptide concentration
(.mu.g/ml) required to induce 100 pg/well of IFN.gamma. (Th1
cytokines) .sup.bMinimum peptide concentration (.mu.g/ml) required
to induce 50 pg/ml of IL10 or IL5 (Th2 cytokines) .sup.cNS,
cytokine levels not significant (<5 pg/ml) .sup.dA relative
binding change of four-fold or more compared to wildtype peptide is
considered significant and is indicated in bold
TABLE-US-00007 TABLE 7 Summary of heteroclitic analogs of MAGE2.170
Heteroclitic Position of B*0702 binding Antigen substitution Type
of substitution Substitution (IC50, nM) SEQ ID NO: MAGE2.170 None
(WT) None 112 SEQ ID NO: 48 MAGE2.170H7 Y --> H
Semi-conservative 7 75 SEQ ID NO: 49 MAGE2.170M7 Y --> M
Semi-conservative 7 69 SEQ ID NO: 50 MAGE2.170G7 Y --> G
Non-conservative 7 105 SEQ ID NO: 51 MAGE2.170E7 Y --> E
Non-conservative 7 186 SEQ ID NO: 52 MAGE2.170D7 Y --> D
Non-conservative 7 1276 SEQ ID NO: 53
Sequence CWU 1
1
5319PRTArtificial SequenceCEA.691 1Ile Met Ile Gly Val Leu Val Gly
Val 1 529PRTArtificial SequenceCEA.691 M3 2Ile Met Met Gly Val Leu
Val Gly Val 1 539PRTArtificial SequenceCEA.691 H5 3Ile Met Ile Gly
His Leu Val Gly Val 1 549PRTArtificial SequenceMAGE3.112 4Lys Val
Ala Glu Leu Val His Phe Leu 1 559PRTArtificial SequenceMAGE3.112 I5
5Lys Val Ala Glu Ile Val His Phe Leu 1 569PRTArtificial
SequenceMAGE3.112 W7 6Lys Val Ala Glu Leu Val Trp Phe Leu 1
5710PRTArtificial SequenceMAGE2.157 7Tyr Leu Gln Leu Val Phe Gly
Ile Glu Val 1 5 10810PRTArtificial SequenceMAGE2.157 I5 8Tyr Leu
Gln Leu Ile Phe Gly Ile Glu Val 1 5 10910PRTArtificial
SequenceMAGE2.157 F5 9Tyr Leu Gln Leu Phe Phe Gly Ile Glu Val 1 5
10109PRTArtificial Sequencep53.149M2 10Ser Met Pro Pro Pro Gly Thr
Arg Val 1 5119PRTArtificial Sequencep53.149M2 C1 11Cys Met Pro Pro
Pro Gly Thr Arg Val 1 5129PRTArtificial Sequencep53.149M2 P7 12Ser
Met Pro Pro Pro Gly Pro Arg Val 1 51311PRTArtificial
Sequencep53.Mu184 13Gly Leu Ala Pro Pro Gln His Leu Ile Arg Val 1 5
101411PRTArtificial Sequencep53.Mu184 T3 14Gly Leu Thr Pro Pro Gln
His Leu Ile Arg Val 1 5 101511PRTArtificial Sequencep53.Mu184 T3,
E6 15Gly Leu Thr Pro Pro Glu His Leu Ile Arg Val 1 5
10169PRTArtificial SequenceHBV Pol455 16Gly Leu Ser Arg Tyr Val Ala
Arg Leu 1 5179PRTArtificial SequenceHBV Pol455 P7 17Gly Leu Ser Arg
Tyr Val Pro Arg Leu 1 5189PRTArtificial SequenceHIV Pol476 18Ile
Leu Lys Glu Pro Val His Gly Val 1 5199PRTArtificial SequenceHIV
Pol476 H3 19Ile Leu His Glu Pro Val His Gly Val 1 5209PRTArtificial
SequenceHIV Pol476L3 20Ile Leu Ile Glu Pro Val His Gly Val 1
5219PRTArtificial Sequencep53.261 21Leu Leu Gly Arg Asp Ser Phe Glu
Val 1 5229PRTArtificial Sequencep53.261 D3 22Leu Leu Asp Arg Asp
Ser Phe Glu Val 1 5239PRTArtificial Sequencep53.261 H3 23Leu Leu
His Arg Asp Ser Phe Glu Val 1 5249PRTArtificial Sequencep53.261 L7
24Leu Leu Gly Arg Asp Ser Leu Glu Val 1 5259PRTArtificial
Sequencep53.261 H7 25Leu Leu Gly Arg Asp Ser His Glu Val 1
5269PRTArtificial Sequencep53.261 N5 26Leu Leu Gly Arg Asn Ser Phe
Glu Val 1 5279PRTArtificial Sequencep53.261 G5 27Leu Leu Gly Arg
Gly Ser Phe Glu Val 1 5289PRTArtificial SequenceNone 28Ala Pro Ala
Ala Ala Ala Ala Ala Tyr 1 52910PRTArtificial sequenceNone 29Lys Val
Phe Pro Tyr Ala Leu Ile Asn Lys 1 5 103013PRTArtificial
Sequence(HBV core) 30Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro
Ile Leu 1 5 103110PRTArtificial Sequence(HBI Core) 31Phe Leu Pro
Ser Asp Phe Phe Asp Ser Val 1 5 103214PRTTetanus toxoid 32Gln Tyr
Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu 1 5
103321PRTPlasmodium falciparum 33Asp Ile Glu Lys Lys Ile Ala Lys
Met Glu Lys Ala Ser Ser Val Phe 1 5 10 15Asn Val Val Asn Ser
203416PRTStreptococcus 18 kD 34Gly Ala Val Asp Ser Ile Leu Gly Gly
Val Ala Thr Tyr Gly Ala Ala 1 5 10 153513PRTArtificial
Sequencepan-DR-binding epitope peptide 35Xaa Lys Xaa Val Ala Ala
Trp Thr Leu Lys Ala Ala Xaa1 5 103613PRTArtificial
Sequencepan-DR-binding epitope peptide 36Xaa Lys Phe Val Ala Ala
Trp Thr Leu Lys Ala Ala Xaa 1 5 103713PRTArtificial
Sequencepan-DR-binding epitope peptide 37Xaa Lys Tyr Val Ala Ala
Trp Thr Leu Lys Ala Ala Xaa 1 5 103810PRTArtificial SequenceHBV
Core.18 epitope 38Phe Leu Pro Ser Asp Phe Phe Pro Ser Val 1 5
10399PRTArtificial SequenceHLA-B7 supermotif bearing peptide 39Ala
Pro Arg Thr Leu Val Tyr Leu Leu 1 5409PRTArtificial SequenceHLA-B7
supermotif bearing peptide 40Ala Pro Glu Thr Leu Val Tyr Leu Leu 1
5419PRTArtificial SequenceHLA-B7 supermotif bearing peptide 41Ala
Pro Arg Thr Trp Val Tyr Leu Leu 1 5429PRTArtificial SequenceHLA-B7
supermotif bearing peptide 42Ala Pro Arg Thr Leu Val Pro Leu Leu 1
54310PRTArtificial SequenceHLA-A3 supermotif bearing peptide 43Lys
Val His Pro Tyr Ala Leu Ile Asn Lys 1 5 104410PRTArtificial
SequenceHLA-A3 supermotif bearing peptide 44Lys Val Phe Pro Gln Ala
Leu Ile Asn Lys 1 5 104510PRTArtificial sequenceHLA-A3 supermotif
bearing peptide 45Lys Val Phe Pro Tyr Ala Lys Ile Asn Lys 1 5
10469PRTArtificial sequenceMAGE3.122 46Lys Val Ala Glu Leu Val His
Phe Leu 1 5479PRTArtificial SequenceHIV Pol.476 47Ile Leu Lys Glu
Pro Val His Gly Phe 1 5489PRTArtificial SequenceMAGE2.170 48Val Pro
Ile Ser His Leu Tyr Ile Leu1 5499PRTArtificial SequenceMAGE2.170 H7
49Val Pro Ile Ser His Leu His Ile Leu1 5509PRTArtificial
SequenceMAGE2.170 M7 50Val Pro Ile Ser His Leu Met Ile Leu1
5519PRTArtificial SequenceMAGE2.170 G7 51Val Pro Ile Ser His Leu
Gly Ile Leu1 5529PRTArtificial SequenceMAGE2.170 E7 52Val Pro Ile
Ser His Leu Glu Ile Leu1 5539PRTArtificial SequenceMAGE2.170 D7
53Val Pro Ile Ser His Leu Asp Ile Leu1 5
* * * * *
References